<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ceftriaxone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ceftriaxone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ceftriaxone: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9229" href="/d/html/9229.html" rel="external">see "Ceftriaxone: Drug information"</a> and <a class="drug drug_patient" data-topicid="11907" href="/d/html/11907.html" rel="external">see "Ceftriaxone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1046122"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>
<div class="block don drugH1Div" id="F53462400"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Use alternative therapy if patient is receiving IV calcium in any form (including parenteral nutrition); administer cautiously to hyperbilirubinemic neonates, especially those born prematurely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>): Preterm and term neonates: IM, IV: 50 mg/kg/dose every 24 hours.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5adafe91-824f-435b-ba72-7add08295e38">Gonococcal infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infections</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>): <b>Note:</b> Administer cautiously to hyperbilirubinemic neonates, especially those born prematurely; alternative agent may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis, asymptomatic neonates born to mothers with gonococcal infection: IM, IV: 25 to 50 mg/kg as a single dose; maximum dose: 250 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Disseminated infection (including sepsis, arthritis, and meningitis) or scalp abscess: </i>IM, IV: 25 to 50 mg/kg/dose every 24 hours. For sepsis, arthritis, or scalp abscess, treat for 7 days; for documented meningitis treat for 10 to 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Ophthalmia neonatorum:</i> IM, IV: 25 to 50 mg/kg as a single dose; maximum dose: 250 mg/dose. <b>Note:</b> May also be used for prophylaxis if erythromycin ointment is not available.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="37fec6e3-fe2f-4af7-9251-f9bbaee625cd">Meningitis, nongonococcal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, nongonococcal:</b> Limited data available; optimal dose not established: <b>Note:</b> IDSA guidelines do not provide ceftriaxone dosing for neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>). Dosing based on an open-label prospective trial of 71 patients (age range: PNA 14 days to 15 years) which included 26 patients diagnosed with meningitis and a pharmacokinetic analysis of 20 neonates and infants (n=12 neonates; including 6 with PNA &lt;14 days) with sepsis or meningitis; both trials reported adequate cerebrospinal fluid penetration and favorable response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6088747','lexi-content-ref-3725639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6088747','lexi-content-ref-3725639'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">PNA &lt;14 days: IV: 50 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">PNA ≥14 days: IV: 100 mg/kg for one dose, followed by 80 to 100 mg/kg/dose every 24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc2855ff-5f21-498a-b2b2-8425feba6b46">Syphilis, congenital</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Syphilis, congenital (alternative agent for confirmed or highly probable congenital syphilis): Note:</b> Only for use when aqueous and procaine penicillin are unavailable (eg, shortage) due to insufficient data for use; if used, close monitoring and follow-up in consultation with an expert are required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 50 to 75 mg/kg/dose every 24 hours; duration dependent on close clinical and serological follow-up (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F148227"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: IM, IV: 50 to 75 mg/kg/<b>day</b> in divided doses every 12 to 24 hours; maximum daily dose: 2,000 mg/<b>day</b>; higher doses are recommended in certain infections (eg, endocarditis, meningitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-AAP.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e2a56fe-ae38-44c3-9cbe-f0cf191e8b37">Chancroid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chancroid:</b> Infants, Children, and Adolescents: IM: 50 mg/kg as a single dose; maximum dose: 250 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6b46673-8570-4914-ad98-b96bd4dd105b">Endocarditis, prophylaxis before invasive dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis before invasive dental procedures (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative agent for use in patients who are unable to take oral medication and who have penicillin or ampicillin allergy (excluding those with a history of anaphylaxis, angioedema, or urticaria) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33853363'])">Ref</a></span>). Recommended only in patients who are at highest risk for infective endocarditis (IE) or adverse outcomes (eg, history of IE, cardiac valve repair using prosthetic valves or material, unrepaired cyanotic congenital heart disease [CHD], left ventricular assist device or implantable heart, repaired CHD with prosthetic material or device during first 6 months after procedure, pulmonary artery valve or conduit placement [eg, Melody valve, Contegra conduit], repaired CHD with residual defects at the site or adjacent to site of prosthetic patch or device, heart transplant recipients with cardiac valvulopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, IM: 50 mg/kg as a single dose administered 30 to 60 minutes prior to dental procedure; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33853363'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment:</b> Children and Adolescents: IV: 50 mg/kg/dose every 12 hours <b>or</b> 80 mg/kg/dose every 24 hours; maximum daily dose: 4,000 mg/<b>day</b>; daily doses over 2,000 mg should be divided into 2 doses. Treat for ≥4 weeks depending on pathogen and valve type; longer durations may be necessary; use in combination with other antibiotics depending on pathogen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20bc5bb0-4207-444d-bcdc-307b9a4c87ca">Epididymitis, acute; empiric treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Epididymitis, acute; empiric treatment: </b>Adolescents: IM: 500 mg as a single dose; 1,000 mg is recommended for patients weighing ≥150 kg. Use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53573596-e9e3-4945-8eee-4664ba4ea8f5">Gonococcal infections, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infections, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated gonococcal infection (cervicitis, pharyngitis, proctitis, and urethritis):</i>
<b>Note:</b> For pharyngeal gonorrhea, a test-of-cure is recommended 7 to 14 days following treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children weighing ≤45 kg: IM, IV: 25 to 50 mg/kg as a single dose; maximum dose: 250 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children weighing &gt;45 kg and Adolescents: IM: 500 mg as a single dose; 1,000 mg is recommended for patients weighing ≥150 kg. If chlamydial infection has not been excluded, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332296','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332296','lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated gonococcal infection (arthritis or arthritis-dermatitis syndrome):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IM, IV: 50 mg/kg/dose every 24 hours for 7 days; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IM, IV: 1,000 mg every 24 hours; may switch to an oral agent (per susceptibility testing) 24 to 48 hours after clinical improvement and treat for a total of ≥7 days. If chlamydial infection has not been excluded, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gonococcal bacteremia</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children weighing ≤45 kg: IM, IV: 50 mg/kg/dose every 24 hours for 7 days; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children weighing &gt;45 kg and Adolescents: IM, IV: 1,000 mg every 24 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gonococcal conjunctivitis</i>: Adolescents: IM: 1,000 mg in a single dose. If chlamydial infection has not been excluded, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 50 to 100 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0676402d-6bcc-48b1-a3ce-53f79c692b71">Lyme disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia</i> spp. infection):</b> Limited data available: Infants, Children, and Adolescents: IV: 50 to 75 mg/kg/dose every 24 hours; maximum dose: 2,000 mg/dose. Duration of therapy depends on clinical syndrome; treat meningitis, radiculopathy, or carditis for 14 to 21 days, and recurrent or refractory arthritis for 14 to 28 days depending on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial: </b>
<b>Note: </b>Per the manufacturer's labeling, doses may be administered IM.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Community-acquired meningitis: </i>Infants, Children, and Adolescents: IV: 80 to 100 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Health care-associated meningitis/ventriculitis: </i>Infants, Children, and Adolescents: IV: 100 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f432b107-cae5-4837-8cf7-e78dcd6458d0">Meningococcal disease, chemoprophylaxis for high-risk contacts</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal disease, chemoprophylaxis for high-risk contacts (following close exposure to patients with invasive meningococcal disease):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;15 years: IM: 125 mg in a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥15 years: IM: 250 mg in a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial treatment (alternative agent for patients who cannot tolerate oral therapy)</i>: IM, IV: 50 mg/kg/dose every 24 hours for 1 to 3 days; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-18246740','lexi-content-ref-10608648','lexi-content-ref-AAP.1','lexi-content-ref-9392401','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-18246740','lexi-content-ref-10608648','lexi-content-ref-AAP.1','lexi-content-ref-9392401','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Failure of initial treatment or suspected/proven penicillin-resistant</i>
<i>Streptococcus pneumoniae</i>: IM, IV: 50 mg/kg/dose every 24 hours for 3 days; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-9869558','lexi-content-ref-11099083','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-9869558','lexi-content-ref-11099083','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab8f1b30-cec2-4012-b46b-cfc140485c7c">Peritonitis, prophylaxis for patients receiving peritoneal dialysis who require dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis), prophylaxis for patients receiving peritoneal dialysis who require dental procedures:</b> Infants, Children, and Adolescents: IM, IV: 50 mg/kg administered 30 to 60 minutes before dental procedure; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (CAP)</b>: Infants &gt;3 months, Children, and Adolescents: IV: 50 to 100 mg/kg/<b>day</b> divided every 12 to 24 hours; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587','lexi-content-ref-Manu.1'])">Ref</a></span>); higher maximum daily doses of 4,000 mg/<b>day</b> are recommended for HIV-exposed/-infected patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2021b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2021b'])">Ref</a></span>). <b>Note:</b> Use as part of appropriate combination therapy if methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) or atypical pathogens are of concern. Use doses on the higher end of the range for penicillin-resistant <i>S. pneumoniae</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Ambulatory patients (alternative agent): Children and Adolescents: IM, IV: 50 mg/kg as a single dose; maximum dose: 1,000 mg/dose; use for patients who are unable to tolerate oral medication, or unlikely to be adherent to the initial doses of antibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23796742','lexi-content-ref-22438350','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23796742','lexi-content-ref-22438350','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe infection requiring hospitalization: Infants, Children, and Adolescents: IV: 25 mg/kg/dose every 12 hours for 10 to 14 days; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ab24c62-d629-4e6e-9748-78dc1196876c">Salmonella species infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Salmonella</i> species infection, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nontyphoidal Salmonella infection</i> (alternative agent): <b>Note:</b> Antibiotic treatment is typically not needed for uncomplicated nontyphoidal <i>Salmonella </i>infection; consider treating infants &lt;3 months of age and persons with immunosuppression, chronic GI tract disease, and significant cardiac or joint disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29053792','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29053792','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non-HIV-infected: Infants, Children, and Adolescents: IM, IV: 75 to 100 mg/kg/<b>day</b> divided every 12 to 24 hours; treat GI infections for 5 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-11170940','lexi-content-ref-28556448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-11170940','lexi-content-ref-28556448'])">Ref</a></span>); maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">HIV-infected: Adolescents: IV: 1,000 mg every 24 hours for ≥7 to 14 days; bacteremia should be treated for ≥14 days (longer if bacteremia persists or infection is complicated); treat patients with CD4 counts &lt;200 cells/mm<sup>3</sup> for 2 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2021a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2021a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Typhoid fever (Salmonella typhi)</i>: <b>Note: </b>Reserve for patients who have failed oral therapy or who have severe disease, intestinal complications, or obtundation and cannot take oral medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11840084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11840084'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: 75 to 80 mg/kg/dose every 24 hours for 5 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-11840084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-11840084'])">Ref</a></span>); maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a8ad991-fed5-4449-a0f4-ee33ac192406">Sexually transmitted infections, prophylaxis following sexual assault</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections, prophylaxis following sexual assault:</b> Adolescents: IM: 500 mg as a single dose; 1,000 mg is recommended in patients weighing ≥150 kg. Use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7febef5a-46fb-4e6b-a370-93a2d7c9a1c1">Shigellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shigellosis:</b> Infants, Children, and Adolescents: IM, IV: 50 to 100 mg/kg/dose every 24 hours for 2 to 5 days; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-WHO.2005','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-WHO.2005','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note: </b>Mild infections typically do not require antibiotic treatment; antibiotics are recommended for patients with severe disease or immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b> Infants, Children, and Adolescents: IM, IV: 50 to 75 mg/kg/<b>day</b> in divided doses every 12 to 24 hours; maximum daily dose: 2,000 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Children and Adolescents: IV: 50 to 75 mg/kg within 60 minutes prior to the procedure; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27c158d1-f522-4d2c-a14b-8b661d97b007">Syphilis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Syphilis (alternative agent): Note:</b> Not considered first-line therapy; use should be reserved for special circumstances with close monitoring and follow-up.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Congenital syphilis</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>): <b>Note:</b> Only for use when aqueous and procaine penicillin are unavailable (eg, shortage) due to insufficient data for use; if used, close monitoring and follow-up in consultation with an expert are required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IM, IV: 75 mg/kg/dose every 24 hours for 10 to 14 days; maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children: IM, IV: 100 mg/kg/dose every 24 hours for 10 to 14 days; maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acquired syphilis (nonpregnant patients with penicillin allergy)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Early syphilis (primary, secondary, and early-latent): Adolescents: IM, IV: 1,000 mg every 24 hours for 10 to 14 days; optimal dose and duration have not been defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2021a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2021a'])">Ref</a></span>). <b>Note</b>: If adherence or follow-up cannot be ensured, patients with penicillin allergy should be desensitized to penicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Neurosyphilis: Adolescents: IM, IV: 1,000 to 2,000 mg every 24 hours for 10 to 14 days; patients infected with HIV should receive 2,000 mg once daily. <b>Note:</b> Patients with penicillin allergy should be desensitized to penicillin whenever possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2021a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2021a'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b> Infants, Children, and Adolescents: IM, IV: 50 mg/kg/dose every 24 hours; maximum dose: 2,000 mg/dose. Treatment duration dependent on age of patient, response to therapy, and extent of involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29292282','lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29292282','lexi-content-ref-Bradley.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084386"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment is generally necessary in renal impairment; <b>Note:</b> If concurrent renal and hepatic dysfunction, a reduced maximum daily dose should be considered; in adults a maximum daily dose ≤2,000 mg/<b>day</b> is suggested.</p>
<p style="text-indent:-2em;margin-left:4em;">Not dialyzable; no supplemental dose is necessary following hemodialysis or peritoneal dialysis; patients with concomitant hepatic dysfunction must be monitored closely for safety and efficacy.</p></div>
<div class="block dohp drugH1Div" id="F51084387"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No adjustment is generally necessary in hepatic impairment; <b>Note:</b> If concurrent renal and hepatic dysfunction, a reduced maximum daily dose should be considered; in adults a maximum daily dose ≤2,000 mg/<b>day</b> is suggested.</p></div>
<div class="block doa drugH1Div" id="F148203"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9229" href="/d/html/9229.html" rel="external">see "Ceftriaxone: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d24df097-0593-42dc-9270-111398adf462">Actinomycosis, severe or extensive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinomycosis, severe or extensive (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 2 g once daily for 4 to 6 weeks, followed by appropriate long-term oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brook.2020','lexi-content-ref-20428643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brook.2020','lexi-content-ref-20428643'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b74db564-f66e-4f55-8b58-9759dc214a0c">Bite wound infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, treatment (animal or human bite) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g once daily <b>or</b> 1 g every 12 hours in combination with an agent appropriate for anaerobes. Duration of treatment for established infection (which may include oral step-down therapy) is typically 5 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2019a','lexi-content-ref-Baddour.2019b','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2019a','lexi-content-ref-Baddour.2019b','lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection:</b> For pathogen-directed therapy of susceptible organisms in the absence of CNS infection:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019'])">Ref</a></span>). For patients with pneumococcal bacteremia, administer 2 g every 12 hours in combination with vancomycin until meningitis is ruled out (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sexton.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sexton.2019a'])">Ref</a></span>). May also be given as empiric therapy for gram-negative bloodstream infection in hemodynamically stable, immunocompetent patients without health care exposures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy:</i> Usual duration is 7 to 14 days; individualize depending on source and extent of infection as well as clinical response. A 7-day duration is recommended for patients with uncomplicated <i>Enterobacteriaceae</i> infection who respond appropriately to antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2019','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2019','lexi-content-ref-30535100'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation (hospitalized patients without risk factors for <i>Pseudomonas aeruginosa</i>) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 g once daily for 5 to 7 days; may switch to oral therapy following clinical improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15219264','lexi-content-ref-GOLD.2019','lexi-content-ref-Sethi.2020','lexi-content-ref-12645831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15219264','lexi-content-ref-GOLD.2019','lexi-content-ref-Sethi.2020','lexi-content-ref-12645831'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 2 g once daily in combination with other appropriate agents. Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15561650','lexi-content-ref-22619242','lexi-content-ref-Weintrob.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15561650','lexi-content-ref-22619242','lexi-content-ref-Weintrob.2019'])">Ref</a></span>). <b>Note:</b> Do not use for empiric therapy of patients at risk for <i>Pseudomonas</i> (eg, significant water exposure, macerated wound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weintrob.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weintrob.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="142a8701-080d-49cd-9f46-814412cd152f">Endocarditis, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis (dental or invasive respiratory tract procedures) (alternative agent for patients with nonsevere, non-IgE-mediated allergy to penicillin who cannot take oral therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 1 g 30 to 60 minutes before procedure; if inadvertently not given prior to the procedure, may be administered up to 2 hours after the procedure. <b>Note:</b> Reserve for select situations (cardiac condition with the highest risk of adverse endocarditis outcomes and procedure likely to result in bacteremia with an organism that can cause endocarditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17446442','lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17446442','lexi-content-ref-33853363'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Enterococcus faecalis, native or prosthetic valve (penicillin-susceptible):</i>
<b>Note:</b> Recommended regimen in patients with or at risk of renal insufficiency (eg, older age, concomitant nephrotoxins) or with aminoglycoside resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>); some experts prefer this regimen for all patients with susceptible enterococcal native valve endocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sexton.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sexton.2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 12 hours for 6 weeks in combination with ampicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316','lexi-content-ref-23392394','lexi-content-ref-Karchmer.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316','lexi-content-ref-23392394','lexi-content-ref-Karchmer.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HACEK organisms, native or prosthetic valve:</i>
<b>IV, IM:</b> 2 g once daily for 4 weeks (native valve) or 6 weeks (prosthetic valve) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Viridans group streptococci (VGS) and Streptococcus gallolyticus (Streptococcus bovis):</i>
<b>IV, IM:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Native valve: Highly penicillin-susceptible (MIC ≤0.12 mcg/mL): 2 g once daily alone for 4 weeks <b>or</b> in combination with gentamicin for 2 weeks for patients with uncomplicated infection, rapid response to therapy, and no underlying renal disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Native valve: Relatively penicillin-resistant (MIC &gt;0.12 to &lt;0.5 mcg/mL), ceftriaxone-susceptible (alternative agent): 2 g once daily for 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Native valve: Penicillin-resistant (MIC ≥0.5 mcg/mL), ceftriaxone-susceptible (alternative agent): 2 g once daily in combination with gentamicin. The duration of this regimen is not well established; infectious diseases consultation recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316','lexi-content-ref-18444825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316','lexi-content-ref-18444825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Prosthetic valve: Highly penicillin-susceptible (MIC ≤0.12 mcg/mL): 2 g once daily for 6 weeks (with or without concomitant gentamicin for the first 2 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Prosthetic valve: Relatively or fully penicillin-resistant (MIC &gt;0.12 mcg/mL), ceftriaxone-susceptible: 2 g once daily in combination with gentamicin for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9474c76-c81a-48ef-b80f-72ce1a0e25f5">Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 to 2 g once daily; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.2019'])">Ref</a></span>). <b>Note:</b> The addition of anaerobic therapy (eg, metronidazole) is recommended if biliary-enteric anastomosis is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infections (eg, appendicitis, diverticulitis, intra-abdominal abscess):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 to 2 g once daily in combination with metronidazole. Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak2019','lexi-content-ref-Pemberton.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak2019','lexi-content-ref-Pemberton.2019'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a47b3dd-219d-422b-bc94-4af729bacffc">Intracranial abscess or spinal epidural abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial abscess (brain abscess or intracranial epidural abscess) or spinal epidural abscess (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 12 hours; for empiric therapy, use in combination with other appropriate agents. Duration generally ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess and 6 to 8 weeks for intracranial epidural abscess (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25075836','lexi-content-ref-11272029','lexi-content-ref-Sexton.2019c','lexi-content-ref-Sexton.2020','lexi-content-ref-Southwick.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25075836','lexi-content-ref-11272029','lexi-content-ref-Sexton.2019c','lexi-content-ref-Sexton.2020','lexi-content-ref-Southwick.2019'])">Ref</a></span>).<b> Note:</b> For postoperative neurosurgical patients and those at risk for <i>P. aeruginosa</i>, other regimens with expanded gram-negative coverage are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Southwick.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Southwick.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0676402d-6bcc-48b1-a3ce-53f79c692b71">Lyme disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia</i> spp. infection) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carditis, severe disease (patients who are symptomatic, have second or third-degree AV block, or have first degree AV block with PR interval ≥300 msec):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g once daily until high-grade AV block resolved and PR interval &lt;300 msec; may switch to oral therapy to complete a total of 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hu.2019','lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hu.2019','lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute neurologic disease (eg, meningitis or radiculopathy), patients requiring hospitalization:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g once daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Late disease, neurologic disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g once daily for 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>); some experts favor a duration of 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hu.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hu.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Recurrent arthritis after adequate oral regimen:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g once daily for 14 days; may extend to 28 days if inflammation is not resolving (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial: </b>As a component of empiric therapy (community-acquired infections in immunocompetent patients) or pathogen-specific therapy (eg, <i>Streptococcus pneumoniae</i> [ceftriaxone MIC &lt;1 mcg/mL]<i>, Neisseria meningitidis</i>, <i>Haemophilus influenzae,</i>
<i>Cutibacterium acnes</i>, and susceptible gram-negative bacilli; alternative agent for certain pathogens):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 12 hours; for empiric therapy, use in combination with other appropriate agents. Treatment duration is 7 to 21 days, depending on causative pathogen(s) and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5cde8906-986a-46af-9e31-d708f4ba0347">Meningococcal disease, chemoprophylaxis after close contact with high-risk patient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal disease, chemoprophylaxis after close contact with high-risk patient (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 250 mg as a single dose. <b>Note: </b>Prophylaxis should be initiated as soon as possible following exposure (ideally &lt;24 hours after identification of index patient) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15917737','lexi-content-ref-AAP.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15917737','lexi-content-ref-AAP.2012'])">Ref</a></span>). Close contacts include persons with prolonged exposure (≥8 hours) in close proximity (&lt;3 feet) to index patient or direct exposure to oral secretions (eg, household contacts, childcare center contacts) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15917737','lexi-content-ref-Apicella.2019','lexi-content-ref-AAP.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15917737','lexi-content-ref-Apicella.2019','lexi-content-ref-AAP.2012'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86facb2c-9b54-4fed-ad52-ae2b39a7da54">Neurobrucellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurobrucellosis (off-label use): IV: </b>2 g every 12 hours for 4 to 6 weeks as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33650077','lexi-content-ref-34734902','lexi-content-ref-22155822','lexi-content-ref-31534908','lexi-content-ref-33370950','lexi-content-ref-27018084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33650077','lexi-content-ref-34734902','lexi-content-ref-22155822','lexi-content-ref-31534908','lexi-content-ref-33370950','lexi-content-ref-27018084'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d31b3c05-03cb-4fcd-8932-e9d1953c0ab8">Odontogenic soft tissue infection, pyogenic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Odontogenic soft tissue infection, pyogenic (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients unable to take penicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g once daily in combination with metronidazole; following clinical improvement, transition to oral step-down therapy and continue antibiotics until resolution, typically for a total of 7 to 14 days. Use in addition to appropriate surgical management (eg, drainage and/or extraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c92ca38-0c20-4ec4-b5f0-113c6ccf7cd2">Osteomyelitis and/or discitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis and/or discitis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> As a component of empiric therapy or pathogen-specific therapy (eg, <i>Streptococci</i> [beta-hemolytic], <i>C. acnes</i>, susceptible gram-negative bacilli):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 24 hours, generally for ≥6 weeks depending on patient-specific factors such as organism, extent of infection, debridement, and clinical response. Shorter courses are appropriate if the affected bone is completely resected (eg, by amputation). For empiric therapy, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-Osmon.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-Osmon.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention, following open fractures (type III [severe contamination or comminution]): </i>
<b>IV:</b> 2 g every 24 hours as part of an appropriate combination regimen; ideally, administer within 6 hours of injury. Duration is 72 hours after injury or up to 24 hours after wound closure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25159242','lexi-content-ref-Schmitt.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25159242','lexi-content-ref-Schmitt.2020'])">Ref</a></span>). <b>Note:</b> For patients with risk for methicillin-resistant<i> S. aureus (</i>MRSA), potential water exposure, or fecal or clostridial contamination, alternative or additional antibiotics are recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schmitt.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schmitt.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (alternative agent for patients with nonsevere, non-IgE-mediated penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 1 to 2 g once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Limb.2019','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Limb.2019','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b> Inpatients without risk factors for <i>P. aeruginosa</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 2 g once daily in combination with other appropriate agent(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-21482566','lexi-content-ref-21482568','lexi-content-ref-22230331','lexi-content-ref-8605897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-21482566','lexi-content-ref-21482568','lexi-content-ref-22230331','lexi-content-ref-8605897'])">Ref</a></span>); 1 g once daily is sufficient for most hemodynamically stable hospitalized patients with community-acquired pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8605897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8605897'])">Ref</a></span>); for critically ill patients, some experts favor the 2 g dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.2019'])">Ref</a></span>). Total duration (which may include oral step-down therapy) is for a minimum of 5 days; patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection:</b> As a component of empiric therapy or pathogen-specific therapy (eg, <i>Streptococci</i> [beta-hemolytic], <i>C. acnes</i>, susceptible gram-negative bacilli):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 24 hours for 4 to 6 weeks; for empiric therapy, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.2019','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.2019','lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="87ad7408-bc55-4acd-a084-2d6dca4330e0">Rat bite fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rat bite fever (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated infection:</i>
<b>IV:</b> 1 g once daily; if patient clinically improves, may switch to an oral antibiotic after 5 to 7 days to complete a 14-day course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-King.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-King.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Serious invasive infection (including bacteremia, meningitis, endocarditis, and other focal organ involvement):</i>
<b>IV:</b> 2 g once daily; for patients with meningitis, increase dose to 2 g twice daily. Duration depends on the site of infection and extent of disease (eg, 4 weeks for endocarditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27777430','lexi-content-ref-King.1','lexi-content-ref-34189044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27777430','lexi-content-ref-King.1','lexi-content-ref-34189044'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8a572e1-fbbc-4c4a-9074-2127a806c755">
<i>Salmonella</i> species infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Salmonella</i> species infection (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Enteric fever (Salmonella typhi and paratyphi):</i> Empiric therapy for severe disease or an alternative directed therapy for quinolone-nonsusceptible infection:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 12 to 24 hours for 10 to 14 days. <b>Note:</b> May be switched to an oral regimen based on susceptibility testing, if available. Geographic location at time of acquisition impacts risk of resistance; ceftriaxone is not recommended if there is concern for extensively drug-resistant <i>Salmonella</i> spp. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26809813','lexi-content-ref-Ryan.2019','lexi-content-ref-WHO.2003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26809813','lexi-content-ref-Ryan.2019','lexi-content-ref-WHO.2003'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nontyphoidal Salmonella GI infection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 to 2 g every 24 hours for 3 to 14 days (7 to 14 days in HIV-infected patients with a CD4 count ≥200 cells/mm<sup>3</sup>). Immunosuppressed patients (eg, HIV-infected with CD4 count &lt;200 cells/mm<sup>3</sup>) warrant a longer duration of treatment (eg, weeks to months). <b>Note:</b> Reserve antibiotic treatment for patients with severe illness or at high risk of invasive disease (eg, extremes of age, immunosuppression); reserve parenteral therapy for those who cannot tolerate oral agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USHHS.2020','lexi-content-ref-Hohmann.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USHHS.2020','lexi-content-ref-Hohmann.2019a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Nontyphoidal Salmonella bloodstream infection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 to 2 g every 24 hours for 14 days. <b>Note:</b> Immunosuppressed patients (eg, HIV-infected with CD4 count &lt;200 cells/mm<sup>3</sup>) and those with an extraintestinal focus of infection warrant a longer duration of treatment (eg, weeks to months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USHHS.2020','lexi-content-ref-Hohmann.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USHHS.2020','lexi-content-ref-Hohmann.2019b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9357c8a8-bc61-4588-803a-17d7cba42c78">Septic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis (as a component of empiric therapy for traumatic bacterial arthritis without risk factors for <i>P. aeruginosa</i>; pathogen-directed therapy for gram-negative bacilli): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g once daily. Total treatment duration is 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy. For empiric therapy, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24703397','lexi-content-ref-Goldenberg.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24703397','lexi-content-ref-Goldenberg.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Chancroid (due to Haemophilus ducreyi) (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 250 mg as a single dose. <b>Note: </b>Efficacy data in patients with HIV are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Empiric treatment following sexual assault (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 500 mg (1 g in patients ≥150 kg) as a single dose, as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epididymitis (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Inpatients: <b>IV:</b> 1 g once daily; use in combination with doxycycline for patients at risk for sexually transmitted infection. May switch to an appropriate oral regimen after patient is afebrile for 24 hours; total duration (including oral step-down therapy) is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eyre.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eyre.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Outpatients: <b>IM:</b> 500 mg (1 g in patients ≥150 kg) as a single dose in combination with doxycycline, or for patients who practice insertive anal sex, levofloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gonococcal infection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Uncomplicated gonorrhea (infection of the cervix, pharynx, rectum, urethra): <b>Note:</b> Coverage for gonococcal infection should be included in empiric regimens for cervicitis or urethritis in patients at high risk for gonorrhea or if the community prevalence of gonorrhea is high (eg, &gt;5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Powell.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Powell.2019'])">Ref</a></span>), and in empiric regimens for proctitis in individuals who practice anal receptive sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM:</b> 500 mg as a single dose; 1 g is recommended for patients weighing ≥150 kg. Give in combination with treatment for chlamydia if it has not been excluded. A test-of-cure (culture or nucleic acid amplification test) is recommended 7 to 14 days after initial treatment of <b>pharyngeal</b> gonorrhea. When treatment failure is suspected (eg, detection of <i>N.</i>
<i> gonorrhoeae</i> after treatment without additional sexual exposure), consult an infectious diseases specialist. Report failures to the CDC through state and local health departments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Uncomplicated gonorrhea (conjunctivitis) (off-label use):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM:</b> 1 g as a single dose. Give in combination with treatment for chlamydia if it has not been excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Sena.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Sena.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Disseminated gonococcal infection (tenosynovitis, dermatitis, polyarthralgia; purulent arthritis) (off-label use):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV</b> (preferred), <b>IM:</b> 1 g once daily. For patients with triad of tenosynovitis, dermatitis, and arthralgia or synovitis, may switch to IM ceftriaxone 500 mg (1 g in patients ≥150 kg) once daily 24 to 48 hours after clinical improvement to complete a total of ≥7 days of therapy. Patients with purulent arthritis often require ≥7 to 14 days of parenteral therapy; duration depends on clinical status and response to therapy. <b>Note:</b> Give in combination with treatment for chlamydia if it has not been excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Klausner.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Klausner.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pelvic inflammatory disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate:<b> IM:</b> 500 mg (1 g in patients ≥150 kg) as a single dose in combination with doxycycline and metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe (including tubo-ovarian abscess): <b>IV:</b> 1 g once daily in combination with doxycycline and metronidazole; after 24 to 48 hours of sustained clinical improvement, transition to oral therapy to complete 14 days of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Syphilis (alternative agent for nonpregnant patients with nonsevere, non-IgE-mediated penicillin allergy) (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Optimal dose/duration not established; use in consultation with an expert in syphilis management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Hicks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Hicks.1'])">Ref</a></span>). Some experts prefer the IV formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hicks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hicks.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Early syphilis (primary, secondary, and early latent [&lt;1-year duration]):<b> IM, IV: </b>1 g once daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29020150','lexi-content-ref-34292926','lexi-content-ref-28658325','lexi-content-ref-15117503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29020150','lexi-content-ref-34292926','lexi-content-ref-28658325','lexi-content-ref-15117503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Late syphilis (late latent [&gt;1-year duration] or tertiary syphilis with normal CSF examination): <b>IM, IV:</b> 1 to 2 g once daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hicks.1','lexi-content-ref-PHAC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hicks.1','lexi-content-ref-PHAC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Neurosyphilis (including ocular and otosyphilis): <b>Note:</b> Penicillin is preferred; reserve ceftriaxone for when penicillin desensitization or challenge is not feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IM, IV:</b> 1 to 2 g once daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>); some experts prefer the 2 g once daily dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26721608','lexi-content-ref-Hicks.1','lexi-content-ref-10722441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26721608','lexi-content-ref-Hicks.1','lexi-content-ref-10722441'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (eg, select surgical site or necrotizing infections):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 2 g once daily, usually as part of an appropriate combination regimen. Duration varies by extent of infection, clinical response, and other patient factors; for necrotizing infection, continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for ≥48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="84feed74-c8b2-4d2a-aba4-591e16cc673d">Spontaneous bacterial peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spontaneous bacterial peritonitis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary prophylaxis:</i>
<b>Note: </b>For patients with advanced cirrhosis and active GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 g once daily; may transition to oral antibiotic prophylaxis when bleeding is controlled and oral intake is resumed. Total duration (including oral agents) is 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-17030175','lexi-content-ref-Runyon.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-17030175','lexi-content-ref-Runyon.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment (alternative agent): </i>
<b>Note: </b>For patients without sepsis or risk for multidrug resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-Runyon.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-Runyon.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g once daily; duration is for 5 to 7 days, as long as fever and pain have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-Runyon.1','lexi-content-ref-Runyon.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-Runyon.1','lexi-content-ref-Runyon.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d38075e1-39f4-4a72-9e69-c27c9fca2398">Surgical prophylaxis, colorectal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis, colorectal (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g within 60 minutes prior to surgical incision in combination with metronidazole. <b>Note: </b>Reserved for locations where gram-negative resistance to first- and second-generation cephalosporins is high (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>). Postoperative prophylaxis is not recommended in clean and clean-contaminated surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f087d636-182c-4b12-9d94-3466357a24a7">Toxic shock syndrome, streptococcal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxic shock syndrome, streptococcal (alternative agent for patients with nonsevere, non-IgE-mediated penicillin allergy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 2 g every 12 hours in combination with clindamycin. Duration of therapy depends on extent and severity of infection and response to treatment; treat patients who are bacteremic for ≥14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stevens.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stevens.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use empirically only in patients who do not have risk factors for multidrug-resistant organisms, critical illness, or suspected urinary tract obstruction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inpatients:</i>
<b> IV:</b> 1 g once daily. Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021','lexi-content-ref-21292654','lexi-content-ref-15150185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021','lexi-content-ref-21292654','lexi-content-ref-15150185'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Outpatients:</i>
<b> IV, IM:</b> 1 g once, followed by 5 to 14 days of appropriate oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021','lexi-content-ref-21292654'])">Ref</a></span>). <b>Note:</b> For patients who are systemically ill or at risk for more severe illness, some experts continue daily parenteral therapy pending culture and susceptibility testing results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991630"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney impairment:</b>
<b>IM, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;15 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>). Use of &gt;2 g/day has not been studied and should be done with close monitoring, especially in patients with concurrent hepatic dysfunction (decreased biliary excretion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6093521','lexi-content-ref-6329080','lexi-content-ref-6093514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6093521','lexi-content-ref-6329080','lexi-content-ref-6093514'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): IV:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine levels. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematological malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>). <b>Note:</b> Dosing based on Monte Carlo simulation.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥150 mL/minute (empiric therapy or organism with minimum inhibitory concentration [MIC] = 2): 2 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30602511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30602511'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b>
<b>IM, IV:</b> Poorly dialyzed; no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>). Use of &gt;2 g/day has not been studied and should be done with close monitoring, especially in patients with concurrent hepatic dysfunction (decreased biliary excretion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6093521','lexi-content-ref-6329080','lexi-content-ref-6093514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6093521','lexi-content-ref-6329080','lexi-content-ref-6093514'])">Ref</a></span>). Alternatively, 2 g thrice weekly post dialysis achieves pharmacodynamic goals when the MIC ≤1 mcg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16640454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16640454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>IM, IV:</b> Poorly dialyzed; no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>). Use of &gt;2 g/day has not been studied and should be done with close monitoring, especially in patients with concurrent hepatic dysfunction (decreased biliary excretion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6093521','lexi-content-ref-6329080','lexi-content-ref-6093514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6093521','lexi-content-ref-6329080','lexi-content-ref-6093514'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT</b>: <b>IM, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency hemodiafiltration):</b>
<b>IM, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988918"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Child-Turcotte-Pugh class A</b>
<b>through C: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3888488','lexi-content-ref-3905752','lexi-content-ref-6093514','lexi-content-ref-2686882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3888488','lexi-content-ref-3905752','lexi-content-ref-6093514','lexi-content-ref-2686882'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54392453"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Ceftriaxone-calcium precipitation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ceftriaxone-calcium precipitation has occurred, leading to fatal lung and kidney damage in premature and term neonates. Urinary sludge <b>(hypercalciuria)</b>, <b>nephrolithiasis</b>, <b>urolithiasis</b>, and <b>acute renal failure</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24664092','lexi-content-ref-24879561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24664092','lexi-content-ref-24879561'])">Ref</a></span>). <b>Gallbladder sludge</b>, <b>cholelithiasis</b>, and pseudolithiasis, as well as subsequent <b>pancreatitis</b>, have also occurred. Most reports have occurred in pediatric patients; however, there are reports in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16185184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16185184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>:</i> Incompatibility with calcium, resulting in ceftriaxone-calcium precipitates; pancreatitis occurs subsequent to biliary obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; 2 to 18 days after last dose for detection via ultrasound of gallbladder sludge, cholelithiasis, or pseudolithiasis in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32144089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32144089'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk</i>
<i> factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16185184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16185184'])">Ref</a></span>); age ≥12 to 24 months (for biliary precipitation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26170682','lexi-content-ref-18246742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26170682','lexi-content-ref-18246742'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses (&gt;40 <b>mg</b>/kg/day or ≥2 <b>g</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26170682','lexi-content-ref-16185184','lexi-content-ref-2227290','lexi-content-ref-18246742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26170682','lexi-content-ref-16185184','lexi-content-ref-2227290','lexi-content-ref-18246742'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer durations of treatment (&gt;5 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16185184','lexi-content-ref-18246742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16185184','lexi-content-ref-18246742'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired gallbladder emptying (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16185184','lexi-content-ref-2227290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16185184','lexi-content-ref-2227290'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Biliary stasis risk factors (eg, major surgery, severe illness, TPN)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection has occurred, including <b>
<i>Clostridioides difficile-</i>associated diarrhea</b> and <b>
<i>Clostridioides difficile</i> colitis</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Variable; may start on the first day of antibiotic therapy or up to 3 months post antibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (third-/fourth-generation cephalosporins among the highest risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors and H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hemolytic anemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune <b>hemolytic anemia</b> has occurred in patients receiving cephalosporins, including ceftriaxone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30359322','lexi-content-ref-25163809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30359322','lexi-content-ref-25163809'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic (ie, induces complement activating drug-dependent antibodies [mainly IgM-type] resulting in immune complexes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30359322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30359322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; occurs several minutes to 7 days after the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30359322','lexi-content-ref-24878619','lexi-content-ref-32144089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30359322','lexi-content-ref-24878619','lexi-content-ref-32144089'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30359322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30359322'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sickle cell disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32144089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32144089'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity with other cephalosporins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30359322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30359322'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions (immediate and delayed) range from maculopapular <b>skin rash</b> to rare cases of <b>anaphylaxis</b> and <b>anaphylactic shock</b>. Severe cutaneous adverse reactions (SCARs), including <b>acute generalized exanthematous pustulosis </b>(AGEP), <b>drug reaction with eosinophilia and systemic symptoms </b>(DRESS),<b> Stevens-Johnson syndrome </b>(SJS), and <b>toxic epidermal necrolysis </b>(TEN) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24028417','lexi-content-ref-27923648','lexi-content-ref-18566552','lexi-content-ref-12773067','lexi-content-ref-31050838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24028417','lexi-content-ref-27923648','lexi-content-ref-18566552','lexi-content-ref-12773067','lexi-content-ref-31050838'])">Ref</a></span>). <b>Urticaria</b> and <b>serum sickness-</b>like reaction have also occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17578881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17578881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are IgE mediated. Delayed hypersensitivity reactions, including maculopapular rash and SCARs, are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Delayed hypersensitivity reactions: Maculopapular reactions: intermediate; occur 7 to 10 days after initiation. Other reactions (including SCARs): varied; occur after 7 to 14 days up to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between penicillins and cephalosporins and among cephalosporins is mostly related to side chain similarity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27016799','lexi-content-ref-29408440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27016799','lexi-content-ref-29408440'])">Ref</a></span>). A meta-analysis showed negligible cross-reactivity between penicillins and third-generation cephalosporins, such as ceftriaxone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17321857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17321857'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Kernicterus</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kernicterus</b> has been reported in neonates, resulting from hyperbilirubinemia (<b>increased serum bilirubin</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Displaces bilirubin from albumin, resulting in higher concentrations of free unconjugated bilirubin, leading to kernicterus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27718120','lexi-content-ref-28814249','lexi-content-ref-21876985','lexi-content-ref-3190184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27718120','lexi-content-ref-28814249','lexi-content-ref-21876985','lexi-content-ref-3190184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Neonates, especially premature infants</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F148166"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin tightness (IM; local)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Induration at injection site (incidence higher with IM), warm sensation at injection site (IM)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (6%), leukopenia (2%), thrombocytosis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (≤1%), tenderness at injection site (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, palpitations, phlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, cholelithiasis, <i>Clostridioides difficile</i> colitis, dysgeusia, dyspepsia, flatulence, gallbladder sludge, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glycosuria, hematuria, vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia, basophilia, decreased prothrombin time, granulocytopenia, hemolytic anemia, lymphocytopenia, lymphocytosis, monocytosis, neutropenia, prolonged prothrombin time, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site phlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dizziness, headache, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Casts in urine, increased serum creatinine, nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, epistaxis, hypersensitivity pneumonitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Salman 2019), allergic dermatitis, erythema multiforme, Stevens-Johnson syndrome (Liberopoulos 2003), toxic epidermal necrolysis (Atanaskovic-Markovic 2013; Lam 2008), urticaria (Baniasadi 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile-</i>associated diarrhea, glossitis, pancreatitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hypercalciuria (Zeng 2020), oliguria (Shen 2014), ureteral obstruction (Lu 2012), urolithiasis (Shen 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Peker 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Calapai 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Hansel 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy (Roncon-Albuquerque 2009), kernicterus<b>, </b>neurotoxicity (including myoclonus [Hagiya 2017] and nonconvulsive status epilepticus [Kim 2012])</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (post renal) (Li 2014; Shen 2014)</p></div>
<div class="block coi drugH1Div" id="F148182"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ceftriaxone, any component of the formulation, or other cephalosporins; <b>do not use in hyperbilirubinemic neonates</b>, particularly those who are premature since ceftriaxone is reported to displace bilirubin from albumin binding sites; concomitant use with intravenous calcium-containing solutions/products in neonates (≤28 days); IV use of ceftriaxone solutions containing lidocaine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F148163"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated INR: May be associated with increased INR (rarely), especially in nutritionally deficient patients, prolonged treatment, hepatic or renal disease. Monitor INR during treatment if patient has impaired synthesis or low stores of vitamin K; supplementation may be needed if clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal/hepatic impairment (concurrent): Use with caution in patients with concurrent hepatic dysfunction (impaired biliary excretion) and severe kidney disease; dosing adjustments may be recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Use extreme caution in neonates due to risk of hyperbilirubinemia, particularly in premature infants (contraindicated in hyperbilirubinemic neonates and neonates &lt;41 weeks postmenstrual age).</p></div>
<div class="block foc drugH1Div" id="F148175"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (50 mL); 40 mg/mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg (1 ea); 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 100 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F148159"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323052"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (cefTRIAXone Sodium in Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $0.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $0.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (cefTRIAXone Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $1.22 - $46.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $2.30 - $91.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 g (per each): $270.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.91 - $15.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $1.16 - $27.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (cefTRIAXone Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $4.97 - $46.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $9.56 - $91.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g (per each): $20.70 - $448.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (cefTRIAXone Sodium-Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM 3.74%(50ML) (per each): $23.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2GM 2.22%(50ML) (per each): $31.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866260"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (50 mL); 40 mg/mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg (1 ea); 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 100 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 g (1 ea)</p></div>
<div class="block adip drugH1Div" id="F53565736"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Rocephin contains 3.6 mEq sodium per gram of ceftriaxone.</p></div>
<div class="block admp drugH1Div" id="F52612388"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Do not coadminister with calcium-containing solutions.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer IM injections deep into a large muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV infusion:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Administer over 60 minutes to decrease risk of bilirubin encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Administer over 30 minutes; shorter infusion times (15 minutes) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3725639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3725639'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Due to reports of precipitation reaction in neonates, do not reconstitute, admix, or coadminister with calcium-containing solutions (eg, LR, Hartmann's solution, parenteral nutrition), even via separate infusion lines/sites or at different times in any neonate. Ceftriaxone should not be diluted or administered simultaneously with any calcium-containing solution via a Y-site in any patient. However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another for use in patients <b>other than neonates</b> if infusion lines are thoroughly flushed (with a compatible fluid) between infusions.</p>
<p style="text-indent:-2em;margin-left:2em;">IV Push: Administration over 2 to 4 minutes has been reported in pediatric patients &gt;11 years and adults primarily in the outpatient setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6312914','lexi-content-ref-3233896','lexi-content-ref-10476138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6312914','lexi-content-ref-3233896','lexi-content-ref-10476138'])">Ref</a></span>) and over 5 minutes in pediatric patients ages newborn to 15 years with meningitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2292206','lexi-content-ref-6088747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2292206','lexi-content-ref-6088747'])">Ref</a></span>). Rapid IVP injection over 5 minutes of a 2,000 mg dose resulted in tachycardia, restlessness, diaphoresis, and palpitations in an adult patient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7919578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7919578'])">Ref</a></span>). IV push administration in young infants may also have been a contributing factor in risk of cardiopulmonary events occurring from interactions between ceftriaxone and calcium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19289450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19289450'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F148179"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Inject deep IM into large muscle mass; a concentration of 250 mg/mL or 350 mg/mL is recommended for all vial sizes except the 250 mg size (250 mg/mL is suggested); can be diluted with 1:1 water or 1% lidocaine for IM administration only.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse as an intermittent infusion over 30 minutes. IV push administration over 1 to 4 minutes has been reported (concentration: 100 mg/mL), primarily in patients outside the hospital setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6312914','lexi-content-ref-3233896','lexi-content-ref-10476138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6312914','lexi-content-ref-3233896','lexi-content-ref-10476138'])">Ref</a></span>), although a 2 g dose administered IV push over 5 minutes resulted in tachycardia, restlessness, diaphoresis, and palpitations in one patient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7919578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7919578'])">Ref</a></span>). Do not coadminister with calcium-containing solutions.</p></div>
<div class="block sts drugH1Div" id="F148192"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Powder for injection: Prior to reconstitution, store at 20°C to 25°C (68°F to 77°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Premixed solution (manufacturer premixed):</p>
<p style="text-indent:-2em;margin-left:4em;">Duplex container: Store the unactivated container at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:4em;">Galaxy container: Store at −20°C (−4°F); once thawed, solutions are stable for 48 hours at 25°C (77°F) or for 21 days at 5°C (41°F). Do not refreeze.</p>
<p style="text-indent:-2em;margin-left:4em;">Frozen premixed solutions: Store at −20°C or below. Once thawed, solutions are stable for 48 hours at 25°C (77°F) or for 21 days at 5°C (41°F). Do not refreeze.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Stability of reconstituted solutions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">10 to 40 mg/mL: Reconstituted in D5W, D10W, NS, or SWFI: Stable for 2 days at room temperature of 25°C (77°F) or for 10 days when refrigerated at 4°C (39°F). Stable for 26 weeks when frozen at −20°C when reconstituted with D5W or NS. Once thawed (at room temperature), solutions are stable for 2 days at room temperature of 25°C (77°F) or for 10 days when refrigerated at 4°C (39°F); does not apply to manufacturer's premixed bags. Do not refreeze. If D5NS or D5<sup>1</sup>/<sub>2</sub>NS are used, solutions are only stable for 2 days at of 25°C (77°F).</p>
<p style="text-indent:-2em;margin-left:4em;">100 mg/mL:</p>
<p style="text-indent:-2em;margin-left:6em;">Reconstituted in D5W, SWFI, or NS: Stable for 2 days at room temperature of 25°C (77°F) or for 10 days when refrigerated at 4°C (39°F).</p>
<p style="text-indent:-2em;margin-left:6em;">Reconstituted in lidocaine 1% solution or bacteriostatic water: Stable for 24 hours at room temperature of 25°C (77°F) or for 10 days when refrigerated at 4°C (39°F).</p>
<p style="text-indent:-2em;margin-left:4em;">250 to 350 mg/mL: Reconstituted in D5W, NS, lidocaine 1% solution, bacteriostatic water, or SWFI: Stable for 24 hours at room temperature of 25°C (77°F) or for 3 days when refrigerated at 4°C (39°F).</p></div>
<div class="block usep drugH1Div" id="F53565953"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of sepsis, meningitis, infections of the lower respiratory tract, acute bacterial otitis media, skin and skin structure, bone and joint, intra-abdominal and urinary tract due to susceptible organisms (FDA approved in infants, children, adolescents, and adults); surgical prophylaxis (FDA approved in adults); documented or suspected uncomplicated gonococcal infection or pelvic inflammatory disease (FDA approved for adults); has also been used for the treatment of endocarditis, Lyme disease, acute bacterial rhinosinusitis, salmonellosis, shigellosis, syphilis, and typhoid fever and prophylaxis of peritonitis in patients undergoing invasive dental procedures.</p></div>
<div class="block mst drugH1Div" id="F148257"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CefTRIAXone may be confused with ceFAZolin, cefoTEtan, cefOXitin, cefTAZidime, Cetraxal</p>
<p style="text-indent:-2em;margin-left:4em;">Rocephin may be confused with Roferon</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Ceftriaxone, when used in neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of kernicterus (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298998"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F148168"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts (Intravenous): May enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate. Management: Use of ceftriaxone is contraindicated in neonates (28 days of age or younger) who require (or are expected to require) treatment with IV calcium-containing solutions. In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ringer's Injection (Lactated): May enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium in the Lactated Ringer's forming an insoluble precipitate. Management: Use of ceftriaxone is contraindicated in neonates (28 days of age or younger) who require (or are expected to require) treatment with IV calcium-containing solutions (ie, LR). In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F148185"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F5952824"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ceftriaxone crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, cephalosporin antibiotics are generally considered compatible for use during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Pregnancy was found to influence the single dose pharmacokinetics of ceftriaxone when administered prior to delivery (Popović 2007). The pharmacokinetics of ceftriaxone following multiple doses in the third trimester are similar to those of nonpregnant patients (Bourget 1993a).</p>
<p style="text-indent:0em;margin-top:2em;">Ceftriaxone is recommended for use in pregnant patients for the treatment of gonococcal infections, Lyme disease, and may be used in certain situations prior to vaginal delivery in patients at high risk for endocarditis (consult current guidelines) (ACOG 2018; CDC [Workowski 2021]; IDSA/AAN/ACR [Lantos 2021]; Lambert 2020). Ceftriaxone should not be used as an alternative agent in penicillin-allergic pregnant patients for the treatment of maternal syphilis or the prevention of congenital syphilis (CDC [Workowski 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53565952"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, platelet count, PT, renal and hepatic function tests periodically; number and type of stools/day for diarrhea; observe for signs and symptoms of anaphylaxis.</p></div>
<div class="block pha drugH1Div" id="F148162"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F148181"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely throughout the body including gallbladder, lungs, bone, bile, CSF (higher concentrations achieved when meninges are inflamed).</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: 0.34 to 0.55 L/kg (Richards 1984).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: 0.32 to 0.4 L/kg (Richards 1984).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: ~6 to 14 L.</p>
<p style="text-indent:-2em;margin-left:4em;">CSF:blood ratio: ~14% (range: 6% to 66%) (Grégoire 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Pleural fluid:serum ratio: ~27% to 29% (range: 1% to 63%) (Goonetilleke 1996).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85% to 95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: 1 to 4 days: 16 hours; 9 to 30 days: 9 hours (Martin 1984).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: 4 to 6.6 hours (Richards 1984).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Normal renal and hepatic function: ~5 to 9 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Renal impairment (mild to severe): ~12 to 16 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (33% to 67% as unchanged drug); feces (as inactive drug).</p></div>
<div class="block phksp drugH1Div" id="F54898029"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC):</p>
<p style="text-indent:-2em;margin-left:8em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:10em;">Enterobacterales: Goal: ≥ ~38% <i>f</i>T &gt; MIC (bacteriostatic); ≥ ~60% to 70% <i>f</i>T &gt; MIC (bactericidal) (Craig 1995; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>S. pneumoniae</i>: ≥ ~40%<i> f</i>T &gt; MIC (bacteriostatic) (Craig 1995; Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:8em;">Population specific:</p>
<p style="text-indent:-2em;margin-left:10em;">Critically ill patients in the ICU: Minimum goal: ≥50%<i> f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Roberts 2014); some experts favor ≥100%<i> f</i>T &gt;4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates and Infants: C<sub>max</sub> (peak): IV: 50 mg/kg, single dose: ~136 to 184 mg/L (Chadwick 1983; McCracken 1983).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children ≤3 years of age: C<sub>max</sub> (peak): IV:</p>
<p style="text-indent:-2em;margin-left:10em;">50 mg/kg, single dose: 207 mg/L (range: 120 to 375 mg/L) (Del Rio 1982).</p>
<p style="text-indent:-2em;margin-left:10em;">50 mg/kg every 12 hours, steady state: 263 mg/L (range: 150 to 410 mg/L) (Del Rio 1982).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: C<sub>max </sub>(peak): IV:</p>
<p style="text-indent:-2em;margin-left:10em;">1 g once daily, steady state: ~136.4 ± 21.2 mg/L (Chiu 2002).</p>
<p style="text-indent:-2em;margin-left:10em;">1 g every 12 hours, steady state: 168 ± 25 mg/L (Pollock 1982).</p>
<p style="text-indent:-2em;margin-left:10em;">2 g every 12 hours, steady state: 280 ± 39 mg/L (Pollock 1982).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Generally &lt;1 hour; varies based on organism (Aldridge 2002; Buxbaum 1996; Craig 1993).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F148186"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Advacef | Axone | Cebact | Ceftriaxone | Megion | Mesporin | Rocephin | Roxcef | Roxone | Samixon | Triaxone</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Acantex | Bioteral | Cefomax | Ceftriaxona biocrom | Ceftriaxona drawer | Ceftriaxona duncan | Ceftriaxona fabra | Ceftriaxona gen me | Ceftriaxona larjan | Ceftriaxona morgan | Ceftriaxona norgreen | Ceftriaxona Richet | Ceftriaxona Surar | Ceftriaz | Ceftrixona Biol | Exempla | Rivacefin | Soltrimox | Triacef</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cefotrix | Ceftriaxon | Ceftriaxon aptapharma | Ceftriaxon Kabi | Ceftriaxon MIP | Ceftriaxon sandoz | Ceftriaxon Torrex | Ceftriaxone kabi | Rocephin biochemie | Rocephin-roche</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone | Ceftriaxone aft | Ceftriaxone alphapharm | Dbl ceftriaxone na | Rocephin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aciphin | Arixon | Axon | Cefixon | Ceftobac | Ceftriaid | Ceftron | Dicephin | Enocef | Eracef | Exephin | G-ceftriax | Holicef | Keptrix | Maxzon | Megion | Nixon | Odatrix | Oricef | Orizone | Parcef | Perix | Rakxon | Rit | Rocephin | Rofecin | Topcef | Traxef | Traxon | Triject | Trimax im | Trimax iv | Trizon | Vertex | Victor | Xone 3 | Xylib</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone | Ceftriaxone actavis | Ceftriaxone hospira | Ceftriaxone sandoz | Rocephine</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Accuzon | Artxon | Cefezone | Ceftral | Ceftriaxone sodique tm | Ceftrix | Cetafor im | Cetafor iv | Cetazone | G ceftria | Mesporin | Odicef | Philco ceftriaxone | Stericef | Utrixone | Zoucef</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxon | Ceftriaxon MIP | Ceftriaxon Rv | Lendacin | Medaxon | Rocephin | Tercef</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amplospec | Ceftriax | Ceftriaxona | Ceftriaxona dissodica | Ceftriaxona dissodica hemieptaidratada | Ceftriaxona sodica | Ceftriona | Celltriaxon | Glicocef | Keftron | Rocefin | Teucef | Triaxin | Triaxon | Triaxton | Trioxina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxon biochemie | Ceftriaxon labatec | Ceftriaxon Orpha | Mesporin | Rocephin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Artxon | Cefezone | Cefmedine | Ceftriaxone aguettant | Desefin | G ceftria | Loydone | Lycef | Mesporin | Nectram | Nova Zone | Onecef | Pantoxon | Rocephine | Saftriax | Starxon | Winject | Zoucef</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acantex | Grifotriaxona</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An di fen | An qu bei shi | An sai long | Cefin | Ceftriaxone | Da li qin | Er ye qin | Er ye song | Feng sai qing | Guo fu mei | Hai qu na | Hai qu song | Hytriaxone | Jin bang | Kai sai xin | Kang kun te | Kang kun xin | Kang li qu | Li jian song | Li kang ke song | Li zhu fen | Luo qin | Medaxone | Nakaxone | Nuo sai fen | Oframax | Qu di | Rocekin | Rocephin | Roselphin | Sai fu song | Shuai ke ning | Tian jia | Wei kang | Xian qin | Xiao ke zhi | Xin da jing | Xin le xin | Ya song | You qu | Yuekang duo zhi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Axtar | Cefaxona | Ceftrian | Ceftriaxona | Ceftriaxona sodica | Ceftridelt | Ceftrinox | Cetroxpira | Dogrel | Dutabil | Rocefin | Sumixona | Triaxin | Trixeft</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cefaxone | Ceftriaxon | Ceftriaxon aptapharma | Ceftriaxon Kabi | Ceftriaxon medochemie | Ceftriaxon medopharm | Ceftriaxon sandoz | Lendacin | Novosef | Oframax | Rocephin | Samixon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cefotrix | Ceftriaxon | Ceftriaxon Actavis | Ceftriaxon bbf | Ceftriaxon DeltaSelect | Ceftriaxon devatis | Ceftriaxon eberth | Ceftriaxon hexal | Ceftriaxon Hikma | Ceftriaxon Pharmore | Ceftriaxon puren | Ceftriaxon qilu | Ceftriaxon Ratiopharm | Ceftriaxon Saar | Ceftriaxon stragen | Rocephin | Rocephine</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Benaxona | Betasporina | Bioteral | Biotrial | Cefamax | Cefaxona | Ceftrian | Ceftriaxin | Ceftriaxona | Ceftriaxona sodico | Ceftrion | Ceftron | Cetriaf | Cloferin | Edelcur | Lutriaxona | Medixone | Oframax | Pralexin | Rocefort | Rocephin | Rowecef | Tracef | Triacef | Triazof | Zetraler</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acrocef | Axtar | Cefacrol iv | Cefaxona | Cefaxone | Ceftrian | Ceftriaxona | Ceftriaxona Richet | Ceftriazona | Ceftridex | Ceftril | Ceftrisin | Ceftristar | Edelcur | Grifotriaxona | Mesporin | Rasertriaxona | Rivacefin | Rocephin | Rowecef | Triaxone</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cefaxone | Ceftriaksons | Ceftriaxone | Ceftriaxone kabi | Lendacin | Medaxone | Mesporin | Rocephin | Tercef</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cefotrix | Ceftriaxone | Epicephin | Kempoxone | Longacef | Mesporin | Nercefaxon | Oframax | Rameceftrax | Rocephin | Sterile ceftriaxone sodium | Triamerican | Triaxone | Trixamarc | Votriaxone | Wintriaxone | Xoraxon | Zoxidel</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxona Combino | Ceftriaxona edigen | Ceftriaxona fresenius kabi | Ceftriaxona Generis | Ceftriaxona ges | Ceftriaxona Ips | Ceftriaxona ldp torlan | Ceftriaxona Mayne | Ceftriaxona normon | Ceftriaxona Reig Jofre | Ceftriaxona rovi | Ceftriaxona Sala | Ceftriaxona salvat | Medaxone | Rocefalin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Axone | Cefort | Ceftazone | Ceftriaxon | Ceftriaxone | Ceftriaxone for injection | Medaxone | Nectram | Rocephin | Sanaxone | Sefixi 1000 | Theoxone | Triaxone</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cefonova | Ceftriaxon Fresenius | Ceftriaxon MIP pharma | Ceftriaxon navamedic | Ceftriaxon Ratiopharm | Ceftriaxon sandoz | Ceftriaxon stragen | Ceftriaxone leiras | Ceftriaxone orion | Rocephalin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone | Ceftriaxone aguettant | Ceftriaxone almus | Ceftriaxone arrow | Ceftriaxone Bayer | Ceftriaxone Biogaran | Ceftriaxone cristers | Ceftriaxone dakota | Ceftriaxone evolugen | Ceftriaxone g gam | Ceftriaxone gerda | Ceftriaxone gnr | Ceftriaxone Irex | Ceftriaxone ivax | Ceftriaxone kabi | Ceftriaxone merck | Ceftriaxone panpharma | Ceftriaxone Qualimed | Ceftriaxone Ratiopharm | Ceftriaxone rpg | Ceftriaxone sandoz | Ceftriaxone teva | Ceftriaxone Winthrop | Ceftriaxone Zydus | Rocephine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone | Ceftriaxone dom | Ceftriaxone panpharma | Rocephin</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Aksone | Cefoson 750 | Medsotriax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Antibacin | Azatyl | Bresec | Ceftriaxone kabi | Ceftriaxone Norma | Ceftriaxone/norma | Ceftrixon | Farcef | Gladius | Glorixone | Infeflox | Labilex | Medaxone | Riaxon | Rocephin | Rolisporin | Travilan | Veracol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Broadced | Cef 3 | Cefin | Ceftriaxone | Ceftron | Medaxonum | Mesporin | Oframax | Rocephin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxon MIP | Ceftriaxone kabi | Lendacin | Medaxone | Rocephin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxon aptapharma | Ceftriaxon eberth | Ceftriaxon Kabi | Ceftriaxon MIP | Ceftriaxon Pharmacenter | Ceftriaxon Torrex | Lendacin | Megion | Rocephin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Biotriax | Bioxon | Broadced | Brospec | Cefaxon | Cefriex | Cefsix | Ceftriaxone | Ceftrimet | Ceftrox | Cefxon | Cephaflox | Criax | Ecotrixon | Elpicef | Erocef | Foricef | Futaxon | Gracef | Incephin | Intricef | Intrix | Racef | Renxon | Rocephin | Socef | Solafexone | Starxon | Terfacef | Termicef | Triacef | Triaxone | Trijec | Trixon | Tyason | Zeftrix</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone | Rocephin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone teva | Keftriaxon | Rocephin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Accuzon | Afzone | Agicef | Alkaceff | Amzone | Ancef | Anocef | Axone | Becef | C fax | C tri | Cadiceft | Cadizone | Cafzone | Cebay trx | Cefaday | Cefaforte | Cefal | Cefamed | Cefast | Cefaxone | Cefbact | Cefbull | Cefera | Cefezone | Cefguard | Cefidiv | Ceflac | Cefnid | Cefnosis | Cefogram | Cefon | Cefra | Ceftisure | Ceftocid | Ceftrax | Ceftriaxone | Ceftrica | Ceftrinject | Ceftrion | Ceftron | Cefxi | Cefzone | Cemax | Cesafe | Cetazone | Cetriax | Cetrone | Cezone | Ciplacef | Comtrix | Controx | E-cef | Ecoceft | Efectal | Efoceft | Ekcef | Eldecet | Elzone | Eracef | Esticef | Extacef-i | Finecef | Finetriax | Fintrax | Futri | Gracef | Gramocef | Grandcef | Grosafe | Gutencef | Haxone | Hetexone | Hicef | Immunox | Ivixone | Kefotax | Kefprox | Kexone | Klokcef | Kocef | Lezone | Livicef | Lorisol | Lucetum | Lyceft | Maczone | Mahacef | Monocef | Monogee | Monopil | Monotax | Morceph | Multi xone | Nexef o | Nosocef | Novaceft | Ocizox | Odicef | Oframax | Omna-one | Onlycef | Oxy | Ozocef | Pancef | Parcef | Pilcef | Powercef | Ranceff | Ritecef | Safelo | Sayotex | Sefzon | Shaxone | Sicef | Spectacef | Stax | Stercef | Supercef | Suprava | Supraxone | Surecef | Taxone | Tejcef | Tericef mono | Torocef | Traxol | Triax | Triocef | Trixon | Trixone | Troyaxone | Trozan | Ultracef | Unitrax | V cef | Vegacef | Winceft | Xone | Xoneceff | Xoy | Zefone | Zetri | Zipod x | Zylocef</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Novosef | Pioxone</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Axobat | Cefoxair | Ceftriaxone | Ceftriaxone almus | Ceftriaxone angenerico | Ceftriaxone biopharma | Ceftriaxone doc | Ceftriaxone eg | Ceftriaxone farma uno | Ceftriaxone Fg | Ceftriaxone Fidia | Ceftriaxone jet | Ceftriaxone kabi | Ceftriaxone merck generics | Ceftriaxone Mgi | Ceftriaxone piam | Ceftriaxone qilu | Ceftriaxone sandoz | Ceftriaxone teva | Ceftriaxone Winthrop | Davixon | Daytrix | Deixim | Diaxone | Eftry | Eraxitron | Fidato | Frineg | Iliaxone | Kappacef | Kocefan | Monoxar | Nilson | Panatrix | Pantoxon | Pokecef | Ragex | Rocefin | Sirtap | Valexime</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Axone | Epicephin | Longacef | Medaxonum | Megion | Novosef | Oframax | Rocephin | Roxcef | Samixon | Triaxone | Veracol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone na | Ceftriaxone sodium np | Ceftriaxone sodium sandoz | Cefxone | Ceroneed | Liasophin | Rocemerck | Rocephin | Rocephin chugai | Rocephin kyorin | Rozeclart | Rozeclart taiyo | Sefirom</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Accuzon | Africef | Apocef t | Arixon | Auroxone | Axone | C tri | Ceftec | Ceftrax | Ceftriagen | Ceftriaxone | Ceftrimed | Ceftrisone | Ceftron | Cetafor im | Cetafor iv | Ciplacef | Da oxone | Desefin | Efectal | Epicephin | Eracef | Esszone | G ceftria | Huacef | Imaxone | Injxone | Inno ceft | Kocef | Lebacef | Marcef | Medicef | Medixone | Mesporin | Monotax | Naxone | Nectram | Nexozone | Nirixone | Oframax | Onecef | Padex | Pancef | Powercef | Protedex | Radicef | Rocephin | Safetax | Samixon | Sky xone | Stacef | Supraxone | Theoxone | Torocef | Traxef | Traxol | Traxon | Triaxobiotic | Triaxone | Trixon | Trixone | Trox | Xone | Zoxon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aju ceftriaxone sodium | Algitrison | Alvogen ceftriaxone sodium | Alzitrison | Aprogen ceftriaxone | Astriaxone | Axon | Binex ceftriaxone sodium | Cefarin | Cefaxon | Cefaxone | Cefcepha | Cefin | Cefkison | Cefkizon | Cefmide | Cefrex | Cefsone | Ceftaxone | Ceftison | Ceftri | Ceftri m | Ceftriaxone | Ceftriaxone boryung | Ceftriaxone daewha | Ceftriaxone koreaunited | Ceftriaxone sodium huons | Ceftriaxone yungjin | Ceftrixone | Ceftron | Cejuxone | Celltrion ceftriaxone | Cerixon | Cetiaxone | Cetriaxone | Cetrison | Daehan new pharm ceftriaxone | Daewoong gomcepin | Dongkoo ceftriaxone sodium | Dongkook ceftriaxone | Dongkwang ceftriaxone | Dongwha ceftriaxone sodium | Etex ceftriaxone sodium | Gentri | Glotriaxone | Hanlim ceftriaxone sodium | Hantrixon | Hawon ceftriaxone | Huviaxon | Icure ceftriaxone | Il yang ceftriaxone sodium | Ildong ceftriaxone | Ilsung ceftriaxone | Inno.n ceftiriaxone | Jeil triaxone | Jw ceftriaxone sodium | K axone | Korus ceftriaxone sodium | Kukje ceftriaxone na | Kyongbo ceftriaxone | Kyongbo ceftriaxone sodium | Lg ceftriaxone | Liasophin | Medica ceftriaxone | Mirae ceftriaxon | Nelaxone | Newcef | Newlaxon | Pesefzu | Porixone | Reyon ceftriaxone | Rocephin | Samsung ceftriaxone sodium | Samsung ceftriaxone sodium hydrate | Spc ceftriaxone sodium | Spotrin | Tiaxin | Triaxone | Tricefaxone | Trisone kit | Trisonkit | Twowintriaxone | Unitiaxone | Wontiaxone | Yooyoung ceftriaxone sodium</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone | Epicephin | Medaxonum | Megion | Mesporin | Rocephin | Roxcef | Samixon | Triaxone</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Axone | Ceftriaxon labatec | Ceftriaxona | Ceftriaxone panpharma | Epicephin | Lebacef | Medaxonum | Mesporin | Rocephin | Rocicare | Rociflex | Sirtap | Travilan | Triaxone | Veracol | Zoxon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Biotrakson | Ceftriaxone | Ceftriaxone kabi | Ceftriaxone MIP | Lendacin | Longaceph | Medaxone | Mesporin | Oframax | Rezaxon | Rocephin | Tercef</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rocephine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaksons | Ceftriaxon MIP | Ceftriaxone | Ceftriaxone bcpp | Ceftriaxone kabi | Ceftriaxone unifarma | Ciplacef | Lendacin | Longaceph | Medaxon | Mesporin | Oframax | Rocephin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Oxone | Rocephine | Triaxon | Trifax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amcef | Amcef im | Aurofox | Auroviax | Axtar | Benaxona | Cefaxona | Cefaxona i.m. | Cefaxona i.v. | Cefraden | Ceftrex | Ceftrex im | Ceftrex iv | Ceftrianol | Ceftriaxona | Ceftriaxona gi | Ceftriaxona gi ken | Ceftriaxona gi mer | Ceftriaxona gi pre | Ceftriaxona le g.i | Ceftrilem | Centrifal | Megion | Primotox | Rocephin | Rocephin IM | Rocephin IV | Tacex | Terbac | Terbac im | Terbac iv | Tindortec | Traxicoll | Triaken | Triaken im | Triaken iv | Triasensi | Triox | Trixona | Trixona i.m. | Trixona i.v. | Trox | Urfyk | Waysul | Xentriac | Xonatil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cef 3 | Cefaxone | Ceftrex | Ceftriaxone | Ceftriaxone zhijun | Celltriaxon | Eftriax | Hoftrex | Mesporin | Oframax | Rocephin | Triaxone | Trixone | Unocef | Vaxcel ceftriaxone</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Avicef | Cefax | Ceferex | Ceftap | Ceftima | Ceftriaxone | Derm ceftriaxone | Duocef | Gebecef | Giga | Gilcef | Gufiphin | Kefoactx | Mon ceftriaxone | Oframax | Oltriaxone | Passcef | Pocco ceftriaxone | Safe trazone | Toc ceftriaxone | Triamax | Tricefin | Triject | Truceef | Vaxcel ceftriaxone | Xapo</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxon | Ceftriaxon Actavis | Ceftriaxon Hikma | Ceftriaxon sandoz | Rocefin | Rocephin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxon | Ceftriaxon copyfarm | Ceftriaxon fresenius kabi | Ceftriaxon MIP | Ceftriaxon navamedic | Ceftriaxone | Rocephalin | Rocephin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aspen Ceftriaxone | Ceftriaxone | Rocephin | Veracol</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Medaxonum</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Betasporina | Braxfar | Broadcef | C fabrox | Cafazolbac | Carotan | Cefabroncol AB | Cefacrol | Cefalogen | Cefater | Cefatriax | Cefax | Cefaxona | Cefopron IM | Ceftrex | Ceftrialiph | Ceftrialis | Ceftriamex | Ceftrian | Ceftriaxon | Ceftriaxona | Ceftribac | Ceftrimax | Cephtronex | Cetaxel | Cetaxel im | Cetranon | Exempla | Grifotriaxona | Oframax | Rocephin | Rylamax | Traxmek | Triaxone | Trizona | Tyriox | Xonacef</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">3 gen | Aglophin | Airefix | Altaxone | Ambiceph | Amkoxone | Armak | Arvexone | Atriax | Auroxone | Axefen | Bactrias | Bettrix | Catarin | Cef 3 | Cefribusin | Ceftibet | Ceftrex | Ceftriabbas | Ceftriaci | Ceftrialis | Ceftriax | Ceftriaxcel | Ceftriaxone | Ceftriaxone disodium | Ceftriaxone hospira | Ceftriaxone Swiss | Ceftriella | Ceftrifil | Ceftrina | Ceftripen | Ceftrix | Ceftrone | Ceftrox | Ceptrocin | Cikedrix | Clovizone | Cotenzo | Cryaxon | Efekton | Eftri | Elixone | Eluxone | Eroxet | Eurosef | Euroxone | Fazactin | Fenadef | Forgram | Forneumo | Fortrixone | Fretriaxone | Gotriaxone | Haxon | Hoftrex | Huanyaw | J-trix | Kairoxon | Kenaxef | Keptrix | Lifetrixone | Maxeftin | Meditrix | Medtri | Megion | Midtrix | Monocrin | Nextchem Ceftriaxone | Norcephin | Novosef | Noxoram | Odicef | Oncef | Onizef | Pantrixon | Peftrin | Pneumosolv | Protriaxone | Puxenon | Racef | Rainoxone | Retrokor | Robixone | Roceftin | Rocephin | Rolaphin | Rophex | Rophin | Samjizon | Sitixon | Supraxone | Sytriaxone | Torocef | Trafexon | Tria G | Triavex | Triax | Triaxon | Tricexone | Trius | Trixcef | Trixchel | Trixophin | Unixone | Vexon | Viatrex | Westriaxone | Xefatrex | Xonocef | Xtenda | Zefaxone | Zentriaxone | Zeptri | Zerone | Zulox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ab xone | Abex | Accucef | Aczon | Aczone | Adazone | Agrocef | Alexon | Alixone | Alphin | Amacef | Amtraxa | Antrix | Araxone | Armasure | Astexone | Avecare | Aventriax | Axitrim | Axon | Bestrix | Biotroxone | Blucef | Burgundy | C-trox | Carazone | Cef 3 | Cefaday | Cefafin | Cefast | Cefcin | Cefin | Cefmark | Cefocef | Cefotrim | Cefotrox | Cefsure | Ceftiheim | Ceftirains | Ceftison | Ceftrex | Ceftriaxone | Ceftril | Ceftrisun | Ceftrix | Ceftro | Ceftrol | Ceftron | Cefxone | Celtis | Cepox | Cerixon | Cesod | Cexzone | Chef | Chroncef | Controx | Ctz | Cyforon | Dayline | Dayzone | Dinaphin | Dinazone | Dv cef | Dynac | Ecocef | Eftriax | Efxone | El cef | Elxone | Esticef | Evazone | Execef | Fortexone | Fotamin | Fotocef | Fraxone | Fredrixone | Genxone | Getofin | H-Nex | Hilixophin | Hytrex | Injectacef | Inocef | Ivax | Jawaz | Jostle | Kanbact | Kefcef | Kocefan | Lendacin | Libor | Longaceph | Lozone | M zone | Macxone | Maxef | Mercefex | Microbin | Naxone | Neocefin | Neogene | Neon | Niasef iv | Nodex | Norbac | Norcef | Novagen | Novosef | Ortazon | Oxidil | P zone | Palzon | Pc Trax | Phyxone | Prezone | Prontox | Prontoxone | Qzon | Ritexone | Rocephin | Rocerex | Rocetrax | Rocimed | Rogofin | Ronil | Ryxon | Salxone | Sanex | Scifect | Seacef | Seftrix | Sergifex | Sixone | Snare | Socephin | Socin | Sodocef | Solara | Soloxone | Sonnet | Sporex | Stag | Stracef | Taxfro | Tecifin | Tefno | Teraxone | Titan | Topcef | Traxef | Traxon | Trexofin | Triax | Tricef | Tricefin | Triject | Trixone | Trizon | Trophin | Tuff | Ty-oxone | Unitrixone | Unixone | Utriaxone | Ventraxin | Ventzon | Vexa | Vitrox | Welcef | Wincef | Wisdon | Wixone | Xephora | Zeftrox | Zintaxon | Zony</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Biotrakson | Ceftriaxon Kabi | Ceftriaxon MIP | Ceftriaxone pliva | Lendacin | Longaceph | Megion | Oframax | Rocephin | Tartriakson</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone | Rocephin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Betasporina | Ceftriaxona | Ceftriaxona Combino | Ceftriaxona Generis | Ceftriaxona medinfar | Ceftriaxona mesporin | Ceftriaxona Sandoz | Ceftriaxona Sidefarma | Ceftriaxone fresenius | Ceriax | Kemudin | Mesporin | Rocephin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bioteral | Braxan | Cefacrol | Cefive im | Cefive iv | Cefticen | Ceftriaxona bioteng | Ceftriaxona cefen i.m. | Ceftriaxona cefen i.v. | Ceftriaxona cipla | Ceftriaxona dutriec | Ceftriaxona emcure | Ceftriaxona eron | Ceftriaxona fada | Ceftriaxona heisecke | Ceftriaxona hospicenter | Ceftriaxona imedic | Ceftriaxona libra | Ceftriaxona medical pharma | Ceftriaxona prosalud | Ceftriaxona quimfa | Ceftriaxona vitalis | Ceftriaxona vivele | Ceftriaz | Ceprox | Edelcur | Grifotriaxona | Ketrax | Rocephin | Soltrimox | Xonatie</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Axone | Cefaxone IM | Desefin | Epicephin | Longacef | Longacef IM | Medaxonum | Megion | Mesporin IM | Mesporin IV | Rocephin IM | Rocephin IV | Roxcef | Samixon IM | Samixon IV | Triaxone IM (Julphar) | Triaxone IV (Julphar)</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cefort | Ceftriaxon | Ceftriaxona | Oframax</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Axone | Azaran | Azarexon | Betasporina | Biotrakson | Cefatrin | Cefaxon | Cefogram | Cefson | Ceftriabol | Ceftriaxone | Ceftriaxone alpa | Ceftriaxone biochemie | Ceftriaxone ds | Ceftriaxone elfa | Ceftriaxone jodas | Ceftriaxone kabi | Ceftriaxone kmp | Ceftriaxone Leksvm | Ceftriaxone promed | Ceftriaxone svm | Ceftriaxone vial | Ceftrifin | Ceftron | Chizon | Forcef | Ificef | Intrasef | Lendacin | Lifaxon | Longaceph | Loraxon | Medaxon | Megion | Movigip | Novosef | Oframax | Roceferin | Rocephin | Stericef | Tercef | Tornaxon | Torocecef | Torocef | Triaxone | Troxone</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cefaject | Cefaxon | Enoxirt | Megion | Mesporin | Rocephin | Roxcef | Roxone | Samixon | Triaxone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cefonova | Ceftriaxon copyfarm | Ceftriaxon fresenius kabi | Ceftriaxon MIP | Ceftriaxon stragen | Ceftriaxon villerton | Rocephalin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cefaxone | Cefin | Ceftriphine | Oframax | Rocephin | Trexofin | Triaxone | Tricefin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Altaxon | Ceftriakson | Ceftriakson actavis | Ceftriakson Apta | Ceftriakson Lek | Lendacin | Olicef</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ceftriakson Lek | Ceftriaxon | Ceftriaxon Kabi | Ceftriaxon sandoz | Ceftron | Lendacin | Megion | Rocephin | Tercef</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Camtaxone | Ceftriaxone</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cef 3 | Cef zone | Ceftrex | Ceftriaxone | Ceftriaxone t p | Ceftrida | Ceftrinox | Ceftriphin | Lephin | Monotax | Oframax | Rinxofay | Rocephin | Rosal | Triacef | Tricef | Tricephin | Trixocaine | Trixone | Trixophin | Uto ceftriaxone | Utofin | Zefaxone</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cefaxone | Ceftriaxone panpharma | Rocephine | Triaxone</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Avisef | Baktisef | Cefaday | Cefamed | Ceforce | Cephaxon | Desefin | Eqiceft | Forsef | Iesef | Nevakson | Novosef | Onceft | Rekson | Rocephin | Rotacef | Tregs | Unacefin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Axonecef | Ceft s | Ceftriaxone | Ceftriaxone kabi | Cetalin | Chef | Rocephin | Sintrix | Tricef | U Ron | Ufin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alcizone | Alvobac | Alvobak | Auroxon | Avexon | Blicef | Bresek | Cefast | Cefaxon | Cefogram | Cefort | Cefotriz | Ceftatime | Ceftrax | Ceftriabol | Ceftriaxon | Ceftriaxon MIP | Ceftriaxone | Ceftriaxone ananta | Ceftriaxone yuria pharm | Ceftriaxonum | Denicef | Diacef | Diacef 1 g | Efmerin | Emcef | Emceph | Emseph | Lavaxon | Lendacin | Longaceph | Loraxon | Loraxone | Medaxon | Medaxone lc | Megion | Oframax | Ontazen-1000 | Parcef | Promocef | Rocephin | Rotacef | Rumixon | Sanaxon | Tercef</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Auroxone | Axone | Cefone | Ceftone | Ceftriaxone | Ceftriaxone for injection | Ceftriaxone sandoz | Ceftrisone | Ceftron | Desefin | Epicephin | Immunox | Medaxonum | Medoxanum | Mesporin | Nectram | Odicef | Powercef | Protedex | Redcephin | Rocephin | Roxone | Sanaxone | Solitax | Solocef | Stacef | Triaxone | Trixone | Vaxcel ceftriaxone | Vexacef | Viriaxone | Zefone</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bioteral | Cefacrol | Ceftriaxona | Ceftriaxona Sandoz | Exempla | Grifotriaxona | Multicef | Rivacefin | Rocephin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Axone | Bioceftrax | Cefaxona | Cefix | Ceftrialin | Ceftriax | Ceftriaxona | Ceftridelt | Cetixona | Cytriax | Eftrival | Immunox | Megion | Oframax | Rocefort | Rocephin | Strixone | Tricefi | Unixona</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Abitrax | Burometam | Cessnari | Fasdizone | Milcerof | Poltraxon | Spreacef | Treadox | Triaxobiotic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone safeline | Cpl alliance ceftriaxone | Fraxone | Fresenius ceftriaxone | Gulf Ceftriaxone | Inoxiphin | Medaxone | Oframax | Pharmacare-ceftriaxone | Rocephin | Rociject | Rokef | Sabax ceftriaxone | Sandoz ceftriaxone | Seftry</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Axone | C tri | Cebay trx | Cefogram | Ceftriaxone | Ciplacef | G ceftria | Lyfaxone | Nectram | Odicef | Oframax | Oka ceftriaxone | Powercef | Stericef | Torocef | Triaxone | Trixone</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ceftriaxone | Immunox | Ivixone | Oframax | Rocephin | Rocetrax | Sefixi 1000 | Traxol | Utrixone | Xone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16887672">
<a name="16887672"></a>Aldridge KE. Comparison of the post-antibiotic effect (PAE) induced by ceftizoxime, ceftriaxone, cefoxitin, ampicillin-sulbactam, and ticarcillin-clavulanate against selected isolates of <i>Bacteroides fragilis</i> and <i>B. thetaiotaomicron</i>. <i>Anaerobe</i>. 2002;8(6):295-299. doi:10.1016/S1075-9964(03)00024-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/16887672/pubmed" id="16887672" target="_blank">16887672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.2019">
<a name="ACOG.2019"></a>American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 199: use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2018;132(3):e103‐e119. doi:10.1097/AOG.0000000000002833</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ryan.2019">
<a name="Ryan.2019"></a>Andrews J, John J, Charles RC. Enteric (typhoid and paratyphoid) fever: Treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apicella.2019">
<a name="Apicella.2019"></a>Apicella M. Treatment and prevention of meningococcal infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 10, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26809813">
<a name="26809813"></a>Arjyal A, Basnyat B, Nhan HT, et al. Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial. <i>Lancet Infect Dis</i>. 2016;16(5):535-545. doi:10.1016/S1473-3099(15)00530-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26809813/pubmed" id="26809813" target="_blank">26809813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007:61, 153.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24028417">
<a name="24028417"></a>Atanasković-Marković M, Medjo B, Gavrović-Jankulović M, Ćirković Veličković T, Nikolić D, Nestorović B. Stevens-Johnson syndrome and toxic epidermal necrolysis in children. <i>Pediatr Allergy Immunol</i>. 2013;24(7):645‐649. doi:10.1111/pai.12121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/24028417/pubmed" id="24028417" target="_blank">24028417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.2019">
<a name="Berbari.2019"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019a">
<a name="Baddour.2019a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2019a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019b">
<a name="Baddour.2019b"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3888488">
<a name="3888488"></a>Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. <i>Clin Pharmacokinet</i>. 1985;10(2):101-143. doi:10.2165/00003088-198510020-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/3888488/pubmed" id="3888488" target="_blank">3888488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17578881">
<a name="17578881"></a>Baniasadi S, Fahimi F, Mansouri D. Serum sickness-like reaction associated with cefuroxime and ceftriaxone. <i>Ann Pharmacother</i>. 2007;41(7):1318‐1319. doi:10.1345/aph.1K146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/17578881/pubmed" id="17578881" target="_blank">17578881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27080992">
<a name="27080992"></a>Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. <i>Clin Infect Dis</i>. 2016;62(10):e51‐e77. doi:10.1093/cid/ciw118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27080992/pubmed" id="27080992" target="_blank">27080992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak2019">
<a name="Barshak2019"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26170682">
<a name="26170682"></a>Bartkowska-Śniatkowska A, Jończyk-Potoczna K, Zielińska M, Rosada-Kurasińska J. Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis. <i>Ther Clin Risk Manag</i>. 2015;11:1035‐1041. doi:10.2147/TCRM.S79419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26170682/pubmed" id="26170682" target="_blank">26170682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6312914">
<a name="6312914"></a>Baumgartner JD, Glauser MP. Single Daily Dose Treatment of Severe Refractory Infections With Ceftriaxone. Cost Savings and Possible Parenteral Outpatient Treatment. <i>Arch Intern Med.</i> 1983;143(10):1868-1873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6312914/pubmed" id="6312914" target="_blank">6312914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3905752">
<a name="3905752"></a>Benoni G, Arosio E, Raimondi MG, Pancera P, Lechi A, Velo GP. Pharmacokinetics of ceftazidime and ceftriaxone and their penetration into the ascitic fluid. <i>J Antimicrob Chemother</i>. 1985;16(2):267-273. doi:10.1093/jac/16.2.267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/3905752/pubmed" id="3905752" target="_blank">3905752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi:10.1093/cid/civ482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site Infection, 2017. <i>JAMA Surg</i>. 2017;152(8):784-791. doi:10.1001/jamasurg.2017.0904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16185184">
<a name="16185184"></a>Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. <i>Pharmacotherapy</i>. 2005;25(10):1389‐1395. doi:10.1592/phco.2005.25.10.1389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/16185184/pubmed" id="16185184" target="_blank">16185184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15917737">
<a name="15917737"></a>Bilukha OO, Rosenstein N; National Center for Infectious Diseases. Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2005;54(RR-7):1-17. <a href="https://www.cdc.gov/mmwr/PDF/rr/rr5407.pdf" target="_blank">http://www.cdc.gov/mmwr/PDF/rr/rr5407.pdf</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15917737/pubmed" id="15917737" target="_blank">15917737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18246740">
<a name="18246740"></a>Biner B, Celtik C, Oner N, et al. The comparison of single-dose ceftriaxone, five-day azithromycin, and ten-day amoxicillin/clavulanate for the treatment of children with acute otitis media. <i>Turk J Pediatr</i>. 2007;49(4):390-396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/18246740/pubmed" id="18246740" target="_blank">18246740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183‐198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33650077">
<a name="33650077"></a>Bosilkovski M, Keramat F, Arapović J. The current therapeutical strategies in human brucellosis. <i>Infection</i>. 2021;49(5):823-832. doi:10.1007/s15010-021-01586-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/33650077/pubmed" id="33650077" target="_blank">33650077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34734902">
<a name="34734902"></a>Bouferraa Y, Bou Zerdan M, Hamouche R, Azar E, Afif C, Jabbour R. Neurobrucellosis: brief review. <i>Neurologist</i>. 2021;26(6):248-252. doi:10.1097/NRL.0000000000000348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/34734902/pubmed" id="34734902" target="_blank">34734902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8431018">
<a name="8431018"></a>Bourget P, Fernandez H, Quinquis V, Delouis C. Pharmacokinetics and protein binding of ceftriaxone during pregnancy. <i>Antimicrob Agents Chemother.</i> 1993a;37(1):54-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/8431018/pubmed" id="8431018" target="_blank">8431018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8453163">
<a name="8453163"></a>Bourget P, Quinquis-Desmaris V, Fernandez H. Ceftriaxone distribution and protein binding between maternal blood and milk postpartum. <i>Ann Pharmacother</i>. 1993b;27(3):294-297. doi:10.1177/106002809302700306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/8453163/pubmed" id="8453163" target="_blank">8453163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2">
<a name="Bradley.2"></a>Bradley JS, Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022:chap. 18.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19289450">
<a name="19289450"></a>Bradley JS, Wassel RT, Lee L, et al. Intravenous Ceftriaxone and Calcium in the Neonate Assessing the Risk for Cardiopulmonary Adverse Events. <i>Pediatrics.</i> 2009;123(4):e609-e613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/19289450/pubmed" id="19289450" target="_blank">19289450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24503131">
<a name="24503131"></a>Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by <i>Clostridium difficile</i>. <i>Gastroenterology</i>. 2014;146(6):1547‐1553. doi:10.1053/j.gastro.2014.01.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/24503131/pubmed" id="24503131" target="_blank">24503131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94‐105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brook.2020">
<a name="Brook.2020"></a>Brook I. Treatment of actinomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25075836">
<a name="25075836"></a>Brouwer MC, Tunkel AR, McKhann GM 2nd, van de Beek D. Brain abscess. <i>N Engl J Med</i>. 2014;371(5):447-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/25075836/pubmed" id="25075836" target="_blank">25075836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326‐2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9007594">
<a name="9007594"></a>Buxbaum A, Georgopoulos A. Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i> and <i>Streptococcus viridans</i>. <i>Infection</i>. 1996;24(6):459-464. doi:10.1007/BF01713048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/9007594/pubmed" id="9007594" target="_blank">9007594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25513979">
<a name="25513979"></a>Calapai G, Imbesi S, Ventura-Spagnolo E, et al. Fatal anaphylactic shock ceftriaxone-induced in a 4-year-old child. <i>Pediatr Emerg Care</i>. 2016;32(1):32-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/25513979/pubmed" id="25513979" target="_blank">25513979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020150">
<a name="29020150"></a>Cao Y, Su X, Wang Q, Xue H, et al. A multicenter study evaluating ceftriaxone and benzathine penicillin g as treatment agents for early syphilis in Jiangsu, China. <i>Clin Infect Dis</i>. 2017;65(10):1683-1688. doi:10.1093/cid/cix611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/29020150/pubmed" id="29020150" target="_blank">29020150</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ceftriaxone injection [prescribing information]. Cherry Hill, NJ: Samson; November 2020.</div>
</li>
<li>
<div class="reference">
                  Ceftriaxone injection [prescribing information]. Lehi, UT: Civica, Inc; February 2021.</div>
</li>
<li>
<div class="reference">
                  Ceftriaxone injection vials [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; July 2018.</div>
</li>
<li>
<div class="reference">
                  Ceftriaxone injection vials [prescribing information]. Pomona, CA: Cephazone; August 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ceftriaxone.2019.09">
<a name="Ceftriaxone.2019.09"></a>Ceftriaxone sodium and dextrose injection Duplex container [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; January 2022.</div>
</li>
<li>
<div class="reference">
                  Ceftriaxone sodium and dextrose injection Galaxy container [prescribing information]. Deerfield, IL: Baxter; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). FAQs for clinicians about <i>C. diff. </i> March 27, 2020. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>. Accessed May 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2015">
<a name="CDC.2015"></a>Centers for Disease Control and Prevention (CDC). Salmonella: Information for Healthcare Professionals and Laboratories. March 9, 2015. <a href="https://www.cdc.gov/salmonella/general/technical.html" target="_blank">https://www.cdc.gov/salmonella/general/technical.html</a>. Accessed December 12, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6294263">
<a name="6294263"></a>Chadwick EG, Yogev R, Shulman ST, Weinfeld RE, Patel IH. Single-dose ceftriaxone pharmacokinetics in pediatric patients with central nervous system infections. <i>J Pediatr.</i> 1983;102(1):134-137. doi:10.1016/s0022-3476(83)80311-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6294263/pubmed" id="6294263" target="_blank">6294263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12461037">
<a name="12461037"></a>Chiu LM, Menhinick AM, Johnson PW, Amsden GW. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers.<i> J Antimicrob Chemother.</i> 2002;50(6):1075-1079. doi:10.1093/jac/dkg003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/12461037/pubmed" id="12461037" target="_blank">12461037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.2019">
<a name="Chow.2019"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. <i>Clin Infect Dis.</i> 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2019b">
<a name="Sexton.2019b"></a>Chu VH. Antimicrobial therapy of left-sided native valve endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15561650">
<a name="15561650"></a>Clay PG, Graham MR, Lindsey CC, Lamp KC, Freeman C, Glaros A. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. <i>Am J Geriatr Pharmacother</i>. 2004;2(3):181-189. doi:10.1016/j.amjopharm.2004.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15561650/pubmed" id="15561650" target="_blank">15561650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24703397">
<a name="24703397"></a>Coiffier G, Alber JD. Is ceftriaxone 2 g once daily a valid treatment option for osteoarticular infections due to Staphylococcus spp., Streptococcus spp., and Gram-negative rods? <i>Joint Bone Spine</i>. 2014;81(3):200-202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/24703397/pubmed" id="24703397" target="_blank">24703397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141‐1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7587056">
<a name="7587056"></a>Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. <i>Diagn Microbiol Infect Dis.</i> 1995;22(1-2):89-96. doi:10.1016/0732-8893(95)00053-d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/7587056/pubmed" id="7587056" target="_blank">7587056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.<i> Clin Infect Dis</i>. 1998;26(1):1-10. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6295262">
<a name="6295262"></a>Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. <i>J Antimicrob Chemother.</i> 1993;31(suppl D):149-158. doi:10.1093/jac/31.suppl_d.149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/8335516/pubmed" id="8335516" target="_blank">8335516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18500456">
<a name="18500456"></a>Dalla Vestra M, Rettore C, Sartore P, et al. Acute septic arthritis: remember gonorrhea. <i>Rheum Int</i>. 2008;29:81-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/18500456/pubmed" id="18500456" target="_blank">18500456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11272029">
<a name="11272029"></a>de Louvois J, Brown EM, Bayston R, Lees PD, Pople LK; Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. The rational use of antibiotics in the treatment of brain abscess: report by the Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. <i>Br J Neurosurg</i>. 2000;14(6):525-530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/11272029/pubmed" id="11272029" target="_blank">11272029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6295262">
<a name="6295262"></a>Del Rio M, McCracken GH Jr, Nelson JD, Chrane D, Shelton S. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. <i>Antimicrob Agents Chemother.</i> 1982;22(4):622-627. doi:10.1128/aac.22.4.622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6295262/pubmed" id="6295262" target="_blank">6295262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951‐1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27718120">
<a name="27718120"></a>Donnelly PC, Sutich RM, Easton R, Adejumo OA, Lee TA, Logan LK. Ceftriaxone-associated biliary and cardiopulmonary adverse events in neonates: a systematic review of the literature. <i>Paediatr Drugs</i>. 2017;19(1):21‐34. doi:10.1007/s40272-016-0197-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27718120/pubmed" id="27718120" target="_blank">27718120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22155822">
<a name="22155822"></a>Erdem H, Ulu-Kilic A, Kilic S, et al. Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study. <i>Antimicrob Agents Chemother</i>. 2012;56(3):1523-1528. doi:10.1128/AAC.05974-11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22155822/pubmed" id="22155822" target="_blank">22155822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eyre.1">
<a name="Eyre.1"></a>Eyre RC. Acute scrotal pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31534908">
<a name="31534908"></a>Fatani DF, Alsanoosi WA, Badawi MA, Thabit AK. Ceftriaxone use in brucellosis: a case series. <i>IDCases</i>. 2019;18:e00633. doi:10.1016/j.idcr.2019.e00633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/31534908/pubmed" id="31534908" target="_blank">31534908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17030175">
<a name="17030175"></a>Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. <i>Gastroenterology</i>. 2006;131(4):1049-1056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/17030175/pubmed" id="17030175" target="_blank">17030175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23392394">
<a name="23392394"></a>Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. <i>Clin Infect Dis</i>. 2013;56(9):1261-1268. doi:10.1093/cid/cit052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23392394/pubmed" id="23392394" target="_blank">23392394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19879276">
<a name="19879276"></a>Feurle G, Junga N, Marth T. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. <i>Gastroenterology</i>. 2010;138:478-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/19879276/pubmed" id="19879276" target="_blank">19879276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23291038">
<a name="23291038"></a>Feurle GE, Moos V, Blacker H, et al. Intravenous ceftriaxone, followed by 12 or three months of oral treatment with trimethoprim sulfamethoxazole in Whipple's disease. <i>J Infect</i>. 2013;66:263-270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23291038/pubmed" id="23291038" target="_blank">23291038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482566">
<a name="21482566"></a>File TM Jr, Low DE, Eckburg PB, et al; FOCUS 1 investigators. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. <i>J Antimicrob Chemother</i>. 2011;66(suppl 3):19-32. doi:10.1093/jac/dkr096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21482566/pubmed" id="21482566" target="_blank">21482566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.2019">
<a name="File.2019"></a>File TM Jr. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15219264">
<a name="15219264"></a>Friedland IR, McCarroll KA, DiNubile MJ, Woods GL. Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia. <i>Pulm Pharmacol Ther</i>. 2004;17(4):199-203. doi:10.1016/j.pupt.2004.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15219264/pubmed" id="15219264" target="_blank">15219264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18444825">
<a name="18444825"></a>Fujitani S, Rowlinson MC, George WL. Penicillin G-resistant viridans group streptococcal endocarditis and interpretation of the American Heart Association's guidelines for the treatment of infective endocarditis. <i>Clin Infect Dis</i>. 2008;46(7):1064-1066. doi:10.1086/529199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/18444825/pubmed" id="18444825" target="_blank">18444825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3233896">
<a name="3233896"></a>Garrelts JC, Ast D, LaRocca J, et al. Postinfusion Phlebitis After Intravenous Push versus Intravenous Piggyback Administration of Antimicrobial Agents. <i>Clin Pharm.</i> 1988;7(10):760-765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/3233896/pubmed" id="3233896" target="_blank">3233896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9869558">
<a name="9869558"></a>Gehanno P, Nguyen L, Barry B, et al. Eradication by ceftriaxone of <i>Streptococcus pneumoniae</i> isolates with increased resistance to penicillin in cases of acute otitis media. <i>Antimicrob Agents Chemother</i>. 1999;43(1):16-20. doi:10.1128/AAC.43.1.16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/9869558/pubmed" id="9869558" target="_blank">9869558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.2019">
<a name="GOLD.2019"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2019">
<a name="Goldenberg.2019"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 9, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9023644">
<a name="9023644"></a>Goonetilleke AK, Dev D, Aziz I, Hughes C, Smith MJ, Basran GS. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes. <i>J Antimicrob Chemother.</i> 1996;38(6):969-976. doi:10.1093/jac/38.6.969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/9023644/pubmed" id="9023644" target="_blank">9023644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grabe.2015">
<a name="Grabe.2015"></a>Grabe M, Bartoletti R, Bjerklund Johansen TE, et al. Guidelines on Urological Infections. 2015. https://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31235630">
<a name="31235630"></a>Grégoire M, Dailly E, Le Turnier P, et al. High-dose ceftriaxone for bacterial meningitis and optimization of administration scheme based on nomogram. <i>Antimicrob Agents Chemother</i>. 2019;63(9):e00634-19. doi:10.1128/AAC.00634-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/31235630/pubmed" id="31235630" target="_blank">31235630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2292206">
<a name="2292206"></a>Grubbauer HM, Dornbusch HJ, Dittrich P, et al. Ceftriaxone Monotherapy for Bacterial Meningitis in Children. <i>Chemotherapy.</i> 1990;36(6):441-447.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/2292206/pubmed" id="2292206" target="_blank">2292206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11170940">
<a name="11170940"></a>Guerrant RL, Van Gilder T, Steiner TS, et al. Practice Guidelines for the Management of Infectious Diarrhea. <i>Clin Infect Dis.</i> 2001;32(3):331-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/11170940/pubmed" id="11170940" target="_blank">11170940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care</i>. 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021">
<a name="Hooton.2021"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28943562">
<a name="28943562"></a>Hagiya H, Miyawaki K, Yamamoto N, et al. Ceftriaxone-induced neurotoxicity in a patient after pancreas-kidney transplantation. <i>Intern Med</i>. 2017;56(22):3103-3107. doi:10.2169/internalmedicine.8774-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28943562/pubmed" id="28943562" target="_blank">28943562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17522387">
<a name="17522387"></a>Halperin JJ, Shapiro ED, Logigian E, et al. Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2007;69(1):91-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/17522387/pubmed" id="17522387" target="_blank">17522387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27923648">
<a name="27923648"></a>Hansel K, Bellini V, Bianchi L, Brozzi J, Stingeni L. Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: An immunohistochemical study. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):808‐810. doi:10.1016/j.jaip.2016.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27923648/pubmed" id="27923648" target="_blank">27923648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18178705">
<a name="18178705"></a>Harwood MI, Womack J, Kaptur R. Primary meningococcal arthritis. <i>J Amer Board Fam Med</i>. 2008;21:66-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/18178705/pubmed" id="18178705" target="_blank">18178705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19209277">
<a name="19209277"></a>Hedge DD, Strain JD, Heins JR, Farver DK. New advances in the treatment of <i>Clostridium difficile</i> infection (CDI). <i>Ther Clin Risk Manag</i>. 2008;4(5):949‐964. doi:10.2147/tcrm.s3145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/19209277/pubmed" id="19209277" target="_blank">19209277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-77. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742‐748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hicks.1">
<a name="Hicks.1"></a>Hicks CB, Clement M. Syphilis: treatment and monitoring. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hohmann.2019a">
<a name="Hohmann.2019a"></a>Hohmann EL. Nontyphoidal Salmonella: gastrointestinal infection and carriage. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hohmann.2019b">
<a name="Hohmann.2019b"></a>Hohmann EL. Nontyphoidal Salmonella bacteremia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 10, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31015812">
<a name="31015812"></a>Hryciw BN, Wright CP, Tan K. Rat bite fever on Vancouver Island: 2010-2016. <i>Can</i>
<i>Commun Dis Rep</i>. 2018;44(9):215-219. doi:10.14745/ccdr.v44i09a05<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/31015812/pubmed" id="31015812" target="_blank">31015812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hu.2019">
<a name="Hu.2019"></a>Hu L. Treatment of Lyme disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6093521">
<a name="6093521"></a>Joos B, Luethy R, Muehlen E, Siegenthaler W. Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections. <i>Am J Med</i>. 1984;77(4C):59-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6093521/pubmed" id="6093521" target="_blank">6093521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6311089">
<a name="6311089"></a>Kafetzis DA, Brater DC, Fanourgakis JE, Voyatzis J, Georgakopoulos P. Ceftriaxone distribution between maternal blood and fetal blood and tissues at parturition and between blood and milk postpartum. <i>Antimicrob Agents Chemother</i>. 1983;23(6):870-873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6311089/pubmed" id="6311089" target="_blank">6311089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Karchmer.2019">
<a name="Karchmer.2019"></a>Karchmer AW, Chu VH. Antimicrobial therapy of prosthetic valve endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27777430">
<a name="27777430"></a>Kawakami Y, Katayama T, Kishida M, Oda W, Inoue Y. A case of streptobacillus moniliformis infection with cutaneous leukocytoclastic vasculitis. <i>Acta Med</i>
<i>Okayama</i>. 2016;70(5):377-381. doi:10.18926/AMO/54596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27777430/pubmed" id="27777430" target="_blank">27777430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22969263">
<a name="22969263"></a>Kim KB, Kim SM, Park W, Kim JS, Kwon SK, Kim HY. Ceftriaxone-induced neurotoxicity: case report, pharmacokinetic considerations, and literature review. <i>J Korean Med Sci</i>. 2012;27(9):1120-1123. doi:10.3346/jkms.2012.27.9.1120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22969263/pubmed" id="22969263" target="_blank">22969263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2012">
<a name="AAP.2012"></a>Kimberlin DW, Brady MT, Jackson MA, Long SS, eds; Committee on Infectious Diseases; American Academy of Pediatrics. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.1">
<a name="King.1"></a>King KY. Rat bite fever. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26721608">
<a name="26721608"></a>Kingston M, French P, Higgins S, et al. UK national guidelines on the management of syphilis 2015. <i>Int J STD AIDS</i>. 2016;27(6):421-446. doi:10.1177/0956462415624059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26721608/pubmed" id="26721608" target="_blank">26721608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klausner.2019">
<a name="Klausner.2019"></a>Klausner JD. Disseminated gonococcal infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 11, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10608648">
<a name="10608648"></a>Klein JO. Review of consensus reports on management of acute otitis media. <i>Pediatr Infect Dis J</i>. 1999;18(12):1152-1155. doi:10.1097/00006454-199912000-00031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/10608648/pubmed" id="10608648" target="_blank">10608648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18566552">
<a name="18566552"></a>Lam A, Randhawa I, Klaustermeyer W. Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem. <i>Allergol Int</i>. 2008;57(3):281‐284. doi:10.2332/allergolint.C-07-55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/18566552/pubmed" id="18566552" target="_blank">18566552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32211414">
<a name="32211414"></a>Lambert JS. An overview of tickborne infections in pregnancy and outcomes in the newborn: The need for prospective studies. <i>Front Med (Lausanne)</i>. 2020;7:72. doi:10.3389/fmed.2020.00072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/32211414/pubmed" id="32211414" target="_blank">32211414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251700">
<a name="33251700"></a>Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(1):1-9. doi:10.1002/acr.24495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/33251700/pubmed" id="33251700" target="_blank">33251700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11099083">
<a name="11099083"></a>Leibovitz E, Piglansky L, Raiz S, Press J, Leiberman A, Dagan R. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. <i>Pediatr Infect Dis J</i>. 2000;19(11):1040-1045. doi:10.1097/00006454-200011000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/11099083/pubmed" id="11099083" target="_blank">11099083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28814249">
<a name="28814249"></a>Le Pichon JB, Riordan SM, Watchko J, Shapiro SM. The neurological sequelae of neonatal hyperbilirubinemia: definitions, diagnosis and treatment of the Kernicterus Spectrum Disorders (KSDs). <i>Curr Pediatr Rev</i>. 2017;13(3):199‐209. doi:10.2174/1573396313666170815100214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28814249/pubmed" id="28814249" target="_blank">28814249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30359322">
<a name="30359322"></a>Leicht HB, Weinig E, Mayer B, Viebahn J, Geier A, Rau M. Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature. <i>BMC Pharmacol Toxicol</i>. 2018;19(1):67. doi:10.1186/s40360-018-0257-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/30359322/pubmed" id="30359322" target="_blank">30359322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24664092">
<a name="24664092"></a>Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W. Ceftriaxone and acute renal failure in children. <i>Pediatrics</i>. 2014;133(4):e917‐e922. doi:10.1542/peds.2013-2103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/24664092/pubmed" id="24664092" target="_blank">24664092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12773067">
<a name="12773067"></a>Liberopoulos EN, Liamis GL, Elisaf MS. Possible cefotaxime-induced Stevens-Johnson syndrome. <i>Ann Pharmacother</i>. 2003;37(6):812‐814. doi:10.1345/aph.1C453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/12773067/pubmed" id="12773067" target="_blank">12773067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media [published correction appears in <i>Pediatrics</i>. 2014;133(2):346-347]. <i>Pediatrics</i>. 2013;131(3):e964-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Limb.2019">
<a name="Limb.2019"></a>Limb CJ, Lustig LR, Durand ML. Acute otitis media in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. <i>Clin Infect Dis. </i>2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28658325">
<a name="28658325"></a>Liu HY, Han Y, Chen XS, et al. Comparison of efficacy of treatments for early syphilis: a systematic review and network meta-analysis of randomized controlled trials and observational studies. <i>PLoS One</i>. 2017;12(6):e0180001. doi:10.1371/journal.pone.0180001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28658325/pubmed" id="28658325" target="_blank">28658325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7919578">
<a name="7919578"></a>Lossos IS, Lossos A. Hazards of Rapid Administration of Ceftriaxone. <i>Ann Pharmacother.</i> 1994;28(6):807-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/7919578/pubmed" id="7919578" target="_blank">7919578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482568">
<a name="21482568"></a>Low DE, File TM Jr, Eckburg PB, et al; FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. <i>J Antimicrob Chemother</i>. 2011;66(suppl 3):iii33-44. doi:10.1093/jac/dkr097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21482568/pubmed" id="21482568" target="_blank">21482568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15024460">
<a name="15024460"></a>Low YM, Leong JL, Tan HK. Paediatric acute epiglottitis re-visited. <i>Singapore Med J.</i> 2003;44(10):539-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15024460/pubmed" id="15024460" target="_blank">15024460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22398584">
<a name="22398584"></a>Lu X, Wu R, Huang X, Zhang Y. Noncontrast multidetector-row computed tomography scanning for detection of radiolucent calculi in acute renal insufficiency caused by bilateral ureteral obstruction of ceftriaxone crystals. <i>J Xray Sci Technol</i>. 2012;20(1):11‐16. doi:10.3233/XST-2012-0315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22398584/pubmed" id="22398584" target="_blank">22398584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10722441">
<a name="10722441"></a>Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. <i>Clin Infect Dis</i>. 2000;30(3):540-544. doi:10.1086/313725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/10722441/pubmed" id="10722441" target="_blank">10722441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6088747">
<a name="6088747"></a>Martin E, Koup JR, Paravicini U, et al. Pharmacokinetics of Ceftriaxone in Neonates and Infants With Meningitis. <i>J Pediatr.</i> 1984;105(3):475-481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6088747/pubmed" id="6088747" target="_blank">6088747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34189044">
<a name="34189044"></a>Matthews C, Ausman S. Rat-bite fever: taking the bite out of a textbook case of <i>Streptobacillus moniliformis</i> blood stream infection. <i>IDCases</i>. 2021;25:e01199. doi:10.1016/j.idcr.2021.e01199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/34189044/pubmed" id="34189044" target="_blank">34189044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30371104">
<a name="30371104"></a>McCann A, Alvi SA, Newman J, et al. Atypical form of cervicofacial actinomycosis involving the skull base and temporal bone. <i>Ann Otol Rhinol Laryngol</i>. 2019;128(2):152-156. doi:10.1177/0003489418808541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/30371104/pubmed" id="30371104" target="_blank">30371104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6301369">
<a name="6301369"></a>McCracken GH Jr, Siegel JD, Threlkeld N, Thomas M. Ceftriaxone pharmacokinetics in newborn infants. <i>Antimicrob Agents Chemother.</i> 1983;23(2):341-343. doi:10.1128/aac.23.2.341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6301369/pubmed" id="6301369" target="_blank">6301369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1‐e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Respir Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.2019">
<a name="Moehring.2019"></a>Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 4, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline [CG183]. September 3, 2014. https://www.nice.org.uk/guidance/cg183. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25163809">
<a name="25163809"></a>Neuman G, Boodhan S, Wurman I, et al. Ceftriaxone-induced immune hemolytic anemia. <i>Ann Pharmacother</i>. 2014;48(12):1594‐1604. doi:10.1177/1060028014548310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/25163809/pubmed" id="25163809" target="_blank">25163809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22230331">
<a name="22230331"></a>Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. <i>Int J Antimicrob Agents</i>. 2012;39(3):240-246. doi:10.1016/j.ijantimicag.2011.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22230331/pubmed" id="22230331" target="_blank">22230331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28315732">
<a name="28315732"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28315732/pubmed" id="28315732" target="_blank">28315732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24878619">
<a name="24878619"></a>Northrop MS, Agarwal HS. Ceftriaxone-induced hemolytic anemia: case report and review of literature. <i>J Pediatr Hematol Oncol</i>. 2015;37(1):e63‐e66. doi:10.1097/MPH.0000000000000181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/24878619/pubmed" id="24878619" target="_blank">24878619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30602511">
<a name="30602511"></a>Ollivier J, Carrié C, d'Houdain N, et al. Are standard dosing regimens of ceftriaxone adapted for critically ill patients with augmented creatinine clearance? <i>Antimicrob Agents Chemother</i>. 2019;63(3):e02134-18. doi:10.1128/AAC.02134-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/30602511/pubmed" id="30602511" target="_blank">30602511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20428643">
<a name="20428643"></a>Onal ED, Altinbas A, Onal IK, et al. Successful outpatient management of pelvic actinomycosis by ceftriaxone: a report of three cases. <i>Braz J Infect Dis</i>. 2009;13(5):391-393. doi:10.1590/S1413-86702009000500016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/20428643/pubmed" id="20428643" target="_blank">20428643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):e1-e25. doi:10.1093/cid/cis803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.2019">
<a name="Osmon.2019"></a>Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 25, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21876985">
<a name="21876985"></a>Pacifici GM. Pharmacokinetics of cephalosporins in the neonate: a review. <i>Clinics (Sao Paulo)</i>. 2011;66(7):1267‐1274. doi:10.1590/s1807-59322011000700024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/21876985/pubmed" id="21876985" target="_blank">21876985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6329080">
<a name="6329080"></a>Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. <i>Antimicrob Agents Chemother</i>. 1984;25(4):438-442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6329080/pubmed" id="6329080" target="_blank">6329080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496200">
<a name="19496200"></a>Peker E, Cagan E, Dogan M. Ceftriaxone-induced toxic hepatitis. <i>World J Gastroenterol</i>. 2009;15(21):2669-2671. doi:10.3748/wjg.15.2669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/19496200/pubmed" id="19496200" target="_blank">19496200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.2019">
<a name="Pemberton.2019"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17321857">
<a name="17321857"></a>Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. <i>Otolaryngol Head Neck Surg</i>. 2007;136(3):340-347. doi:10.1016/j.otohns.2006.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/17321857/pubmed" id="17321857" target="_blank">17321857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6295268">
<a name="6295268"></a>Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ Jr. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults. <i>Antimicrob Agents Chemother.</i> 1982;22(5):816-823. doi:10.1128/aac.22.5.816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6295268/pubmed" id="6295268" target="_blank">6295268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34583654">
<a name="34583654"></a>Pongsuttiyakorn S, Kamolvit W, Limsrivanichakorn S, Phothisirisakulwong A, Wangchinda W. Rat bite fever due to Streptobacillus notomytis complicated by meningitis and spondylodiscitis: a case report. <i>BMC Infect Dis</i>. 2021;21(1):1017. doi:10.1186/s12879-021-06715-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/34583654/pubmed" id="34583654" target="_blank">34583654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10476138">
<a name="10476138"></a>Poole S, Nowobilski-Vasilios A, Free F. Intravenous Push Medications in the Home. <i>J Intraven Nurs.</i> 1999;22(4):209-215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/10476138/pubmed" id="10476138" target="_blank">10476138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18021337">
<a name="18021337"></a>Popović J, Grujić Z, Sabo A. Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women. <i>J Clin Pharm Ther</i>. 2007;32(6):595-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/18021337/pubmed" id="18021337" target="_blank">18021337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Powell.2019">
<a name="Powell.2019"></a>Powell AM, Nyirjesy P. Acute cervicitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33370950">
<a name="33370950"></a>Powers HR, Nelson JR, Alvarez S, Mendez JC. Neurobrucellosis associated with feral swine hunting in the southern United States. <i>BMJ Case Rep</i>. 2020;13(12):e238216. doi:10.1136/bcr-2020-238216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/33370950/pubmed" id="33370950" target="_blank">33370950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada (PHAC). Syphilis guide: key information and resources. <a href="https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/syphilis.html" target="_blank">https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/syphilis.html</a>. Updated December 12, 2021. Accessed April 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15505773">
<a name="15505773"></a>Raad J, Peacock JE. Septic arthritis in the adult caused by Streptococcus pneumoniae: a report of 4 cases and review of the literature. <i>Semin Arthritis Rheum</i>. 2004;34:559-569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15505773/pubmed" id="15505773" target="_blank">15505773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6329638">
<a name="6329638"></a>Richards DM, Heel RC, Brogden RN, et al. Ceftriaxone: A Review of Its Antibacterial Activity, Pharmacological Properties and Therapeutic Use. <i>Drugs. </i>1984;27(6):469-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6329638/pubmed" id="6329638" target="_blank">6329638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rocephin.2018.07">
<a name="Rocephin.2018.07"></a>Rocephin (ceftriaxone sodium) [prescribing information]. South San Francisco, CA: Genentech; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25159242">
<a name="25159242"></a>Rodriguez L, Jung HS, Goulet JA, Cicalo A, Machado-Aranda DA, Napolitano LM. Evidence-based protocol for prophylactic antibiotics in open fractures: improved antibiotic stewardship with no increase in infection rates. <i>J Trauma Acute Care Surg</i>. 2014;77(3):400-407. doi:10.1097/TA.0000000000000398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/25159242/pubmed" id="25159242" target="_blank">25159242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25930196">
<a name="25930196"></a>Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. <i>J Allergy Clin Immunol</i>. 2015;136(3):685‐691.e3. doi:10.1016/j.jaci.2015.03.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/25930196/pubmed" id="25930196" target="_blank">25930196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27016799">
<a name="27016799"></a>Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Caruso C, Quaratino D. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. <i>J Allergy Clin Immunol</i>. 2016;138(1):179‐186. doi:10.1016/j.jaci.2016.01.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27016799/pubmed" id="27016799" target="_blank">27016799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29408440">
<a name="29408440"></a>Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quaratino D, Gaeta F. Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated hypersensitivity to penicillins. <i>J Allergy Clin Immunol Pract</i>. 2018;6(5):1662‐1672. doi:10.1016/j.jaip.2018.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/29408440/pubmed" id="29408440" target="_blank">29408440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19299850">
<a name="19299850"></a>Roncon-Albuquerque R Jr, Pires I, Martins R, Real R, Sousa G, von Hafe P. Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection. <i>Neth J Med</i>. 2009;67(2):72-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/19299850/pubmed" id="19299850" target="_blank">19299850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11310807">
<a name="11310807"></a>Roson B, Carratala J, Tubau F. Usefulness of beta-lactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. <i>Microb Drug Resist</i>. 2001;7(1):85-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/11310807/pubmed" id="11310807" target="_blank">11310807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.1">
<a name="Runyon.1"></a>Runyon BA; American Association for the Study of Liver Diseases Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. https://www.aasld.org/sites/default/files/2019-06/AASLDPracticeGuidelineAsciteDuetoCirrhosisUpdate2012Edition4_.pdf. American Association for the Study of Liver Diseases. Published 2013. Accessed May 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.2">
<a name="Runyon.2"></a>Runyon BA. Spontaneous bacterial peritonitis in adults: treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31050838">
<a name="31050838"></a>Salman A, Yucelten D, Akin Cakici O, Kepenekli Kadayifci E. Acute generalized exanthematous pustulosis due to ceftriaxone: Report of a pediatric case with recurrence after positive patch test. <i>Pediatr Dermatol</i>. 2019;36(4):514‐516. doi:10.1111/pde.13838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/31050838/pubmed" id="31050838" target="_blank">31050838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8129435">
<a name="8129435"></a>Sawyer SM, Johnson PD, Hogg GG, et al. Successful treatment of epiglottitis with two doses of ceftriaxone. <i>Arch Dis Child.</i> 1994;70(2):129-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/8129435/pubmed" id="8129435" target="_blank">8129435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schmitt.2020">
<a name="Schmitt.2020"></a>Schmitt SK. Osteomyelitis associated with open fractures in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8605897">
<a name="8605897"></a>Segev S, Raz R, Rubinstein E, et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. <i>Eur J Clin Microbiol Infect Dis</i>. 1995;14(10):851-855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/8605897/pubmed" id="8605897" target="_blank">8605897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sena.1">
<a name="Sena.1"></a>Seña AC, Cohen MS. Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae</i> infection) in adults and adolescents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.2020">
<a name="Sethi.2020"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2019a">
<a name="Sexton.2019a"></a>Sexton DJ. Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 25, 2019a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2019c">
<a name="Sexton.2019c"></a>Sexton DJ, Sampson JH. Intracranial epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2020">
<a name="Sexton.2020"></a>Sexton DJ, Sampson JH. Spinal epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 7, 2020d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24879561">
<a name="24879561"></a>Shen X, Liu W, Fang X, et al. Acute kidney injury caused by ceftriaxone-induced urolithiasis in children: a single-institutional experience in diagnosis, treatment and follow-up. <i>Int Urol Nephrol</i>. 2014;46(10):1909‐1914. doi:10.1007/s11255-014-0742-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/24879561/pubmed" id="24879561" target="_blank">24879561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2227290">
<a name="2227290"></a>Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. <i>Gastroenterology</i>. 1990;99(6):1772‐1778. doi:10.1016/0016-5085(90)90486-k<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/2227290/pubmed" id="2227290" target="_blank">2227290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16640454">
<a name="16640454"></a>Simon N, Dussol B, Sampol E, et al. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. <i>Clin Pharmacokinet</i>. 2006;45(5):493-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/16640454/pubmed" id="16640454" target="_blank">16640454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15117503">
<a name="15117503"></a>Smith NH, Musher DM, Huang DB, et al. Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. <i>Int J STD AIDS</i>. 2004;15(5):328-332. doi:10.1177/095646240401500511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15117503/pubmed" id="15117503" target="_blank">15117503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis. </i>2010;50(12):1695]. <i>Clin Infect Dis.</i> 2010;15;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Southwick.2019">
<a name="Southwick.2019"></a>Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18246742">
<a name="18246742"></a>Soysal A, Eraşov K, Akpinar I, Bakir M. Biliary precipitation during ceftriaxone therapy: frequency and risk factors. <i>Turk J Pediatr</i>. 2007;49(4):404‐407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/18246742/pubmed" id="18246742" target="_blank">18246742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332296">
<a name="33332296"></a>St. Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. <i>MMWR Morb Mortal Wkly Rep</i>. 2020;69(50):1911-1916. doi:10.15585/mmwr.mm6950a6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/33332296/pubmed" id="33332296" target="_blank">33332296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8413414">
<a name="8413414"></a>Stamm WE, Hooton TM. Management of urinary tract infections in adults. <i>N Engl J Med</i>. 1993;329(18):1328-1334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/8413414/pubmed" id="8413414" target="_blank">8413414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11840084">
<a name="11840084"></a>Stephens I, Levine MM. Management of typhoid fever in children. <i>Pediatr Infect Dis J.</i> 2002;21(2):157-158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/11840084/pubmed" id="11840084" target="_blank">11840084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stevens.2019">
<a name="Stevens.2019"></a>Stevens DL. Invasive group A streptococcal infection and toxic shock syndrome: epidemiology, clinical manifestations, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 27, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6093514">
<a name="6093514"></a>Stoeckel K, Koup JR. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. <i>Am J Med</i>. 1984;77(4C):26-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/6093514/pubmed" id="6093514" target="_blank">6093514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35930502">
<a name="35930502"></a>Tajerian A, Sofian M, Zarinfar N, Ramezani A. Manifestations, complications, and treatment of neurobrucellosis: a systematic review and meta-analysis. <i>Int J Neurosci</i>. 2022:1-11. doi:10.1080/00207454.2022.2100776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/35930502/pubmed" id="35930502" target="_blank">35930502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis</i>. 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USHHS.2020">
<a name="USHHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2021a">
<a name="HHS.2021a"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated August 18, 2021. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2021b">
<a name="HHS.2021b"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1‐10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9392401">
<a name="9392401"></a>Varsano I, Volovitz B, Horev Z, et al. Intramuscular ceftriaxone compared with oral amoxicillin-clavulanate for treatment of acute otitis media in children. <i>Eur J Pediatr</i>. 1997;156(11):858-863. doi:10.1007/s004310050731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/9392401/pubmed" id="9392401" target="_blank">9392401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.2019">
<a name="Vollmer.2019"></a>Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3190184">
<a name="3190184"></a>Wadsworth SJ, Suh B. In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns. <i>Antimicrob Agents Chemother</i>. 1988;32(10):1571‐1575. doi:10.1128/aac.32.10.1571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/3190184/pubmed" id="3190184" target="_blank">3190184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796742">
<a name="23796742"></a>Wald ER, Applegate KE, Bordley C, et.al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1-18 years. <i>Pediatrics</i>. 2013;132:e262-e280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/23796742/pubmed" id="23796742" target="_blank">23796742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update. <i>Perit Dial Int.</i> 2012, 32(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi: 10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.2019">
<a name="Weintrob.2019"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15150185">
<a name="15150185"></a>Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. <i>J Antimicrob Chemother</i>. 2004;53(suppl 2):ii67-ii74. doi:10.1093/jac/dkh208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/15150185/pubmed" id="15150185" target="_blank">15150185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28556448">
<a name="28556448"></a>Wen SC, Best E, Nourse C. Non-typhoidal Salmonella infections in children: Review of literature and recommendations for management. <i>J Paediatr Child Health</i>. 2017;53(10):936-941. doi:10.1111/jpc.13585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28556448/pubmed" id="28556448" target="_blank">28556448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12645831">
<a name="12645831"></a>Wilson R, Langan C, Ball P, Bateman K, Pypstra R; Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. <i>Respir Med</i>. 2003;97(3):242-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/12645831/pubmed" id="12645831" target="_blank">12645831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17446442">
<a name="17446442"></a>Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in <i>Circulation</i>. 2007;116(15):e376-e377]. <i>Circulation.</i> 2007;116(15):1736-1754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/17446442/pubmed" id="17446442" target="_blank">17446442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33853363">
<a name="33853363"></a>Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(20):e963-e978. doi:10.1161/CIR.0000000000000969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/33853363/pubmed" id="33853363" target="_blank">33853363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep. </i>2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2003">
<a name="WHO.2003"></a>World Health Organization (WHO). Background document: the diagnosis, treatment and prevention of typhoid fever. http://apps.who.int/iris/bitstream/10665/68122/1/WHO_V-B_03.07_eng.pdf. Published May 2003. Accessed February 4, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2005">
<a name="WHO.2005"></a>World Health Organization (WHO). Guidelines for the control of shigellosis, including epidemics due to <i>Shigella dysenteriae</i> type 1. http://apps.who.int/iris/bitstream/10665/43252/1/924159330X.pdf?ua=1. Published 2005. Accessed May 17, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512795">
<a name="27512795"></a>World Health Organization (WHO). Guidelines for the Treatment of<i> Neisseria gonorrhoeae.</i> Geneva, Switzerland: World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27512795/pubmed" id="27512795" target="_blank">27512795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus fourteen days of antibiotic therapy for uncomplicated Gram-negative bacteremia: a non-inferiority randomized controlled trial. <i>Clin Infect Dis</i>. Published online December 11, 2018. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29517808">
<a name="29517808"></a>Yang MS, Kang DY, Seo B, et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: A large multicenter retrospective cohort study. <i>Allergy</i>. 2018;73(9):1833‐1841. doi:10.1111/all.13435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/29517808/pubmed" id="29517808" target="_blank">29517808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3725639">
<a name="3725639"></a>Yogev R, Shulman ST, Chadwick EG, et al. Once Daily Ceftriaxone for Central Nervous System Infections and Other Serious Pediatric Infections. <i>Pediatr Infect Dis.</i> 1986;5(3):298-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/3725639/pubmed" id="3725639" target="_blank">3725639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2686882">
<a name="2686882"></a>Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. <i>Clin Pharmacokinet</i>. 1989;17(4):223-235. doi:10.2165/00003088-198917040-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/2686882/pubmed" id="2686882" target="_blank">2686882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32144089">
<a name="32144089"></a>Zeng L, Wang C, Jiang M, et al. Safety of ceftriaxone in paediatrics: a systematic review. <i>Arch Dis Child</i>. 2020;archdischild-2019-317950. Published online March 6, 2020. doi:10.1136/archdischild-2019-317950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/32144089/pubmed" id="32144089" target="_blank">32144089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27018084">
<a name="27018084"></a>Zhao S, Cheng Y, Liao Y, Zhang Z, Yin X, Shi S. Treatment efficacy and risk factors of neurobrucellosis. <i>Med Sci Monit</i>. 2016;22:1005-1012. doi:10.12659/msm.897947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/27018084/pubmed" id="27018084" target="_blank">27018084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28768443">
<a name="28768443"></a>Zheng N, Wang W, Zhang JT, et al. Neurobrucellosis. <i>Int J Neurosci</i>. 2018;128(1):55-62. doi:10.1080/00207454.2017.1363747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftriaxone-pediatric-drug-information/abstract-text/28768443/pubmed" id="28768443" target="_blank">28768443</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13136 Version 499.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
